

Open Research Online

The Open University's repository of research publications and other research outputs

The molecular basis of occupational allergy.

Thesis

How to cite:

Cawley, Christopher John (1985). The molecular basis of occupational allergy. BPhil thesis The Open University.

For guidance on citations see [FAQs](#).

© 1984 The Author



<https://creativecommons.org/licenses/by-nc-nd/4.0/>

Version: Version of Record

Link(s) to article on publisher's website:

<http://dx.doi.org/doi:10.21954/ou.ro.000100e7>

Copyright and Moral Rights for the articles on this site are retained by the individual authors and/or other copyright owners. For more information on Open Research Online's data [policy](#) on reuse of materials please consult the policies page.

oro.open.ac.uk

UNRESTRICTED

THE MOLECULAR BASIS OF
OCCUPATIONAL ALLERGY

Christopher John Cawley B.Sc., MIEH., MRSH.

THESIS FOR THE DEGREE OF BACHELOR OF PHILOSOPHY

BIOLOGY : Immunochemistry

DECEMBER 1984

Authors Number : HDH 2243

Date of Submission : December 1984

Date of Award : 25. 11. 85

ProQuest Number: 27919385

All rights reserved

INFORMATION TO ALL USERS

The quality of this reproduction is dependent on the quality of the copy submitted.

In the unlikely event that the author did not send a complete manuscript and there are missing pages, these will be noted. Also, if material had to be removed, a note will indicate the deletion.



ProQuest 27919385

Published by ProQuest LLC (2020). Copyright of the Dissertation is held by the Author.

All Rights Reserved.

This work is protected against unauthorized copying under Title 17, United States Code
Microform Edition © ProQuest LLC.

ProQuest LLC
789 East Eisenhower Parkway
P.O. Box 1346
Ann Arbor, MI 48106 - 1346

ABSTRACT

The problem of occupational allergy has only been highlighted in recent years. Diseases and disorders arising from acute exposure to large quantities of chemicals and concern over their potential toxic properties generally overshadow considerations of likely allergic reactions and the possibility of sensitisation developing. This thesis summarises the basic mechanisms of immunity and allergy and lists the substances which have given rise to sensitisation and allergic reactions in workers exposed to them. The literature covering allergy and sensitisation (including case histories of workers, animal studies and laboratory investigations) to particular organic chemicals encountered in occupational environments is reviewed. The mechanisms by which these chemicals stimulate allergic reactions in the body are discussed with particular reference to the chemical structure and molecular configuration of the chemicals. Basic physical data, structural formulae, the adverse reactions reported and related details are tabulated for each chemical. Occupational allergy to acid anhydrides is considered in more detail and typical case histories of sensitised workers given. The question of sensitisation generally is discussed. Recommendations for control measures to prevent or alleviate cases of occupational allergy, on improvements in the screening of workers and for the wider availability of information on the subject are made. Tests used in allergy investigations are summarised and a glossary of medical and related terms is given.

CONTENTS

CHAPTER	PAGE
1 INTRODUCTION	1
2 IMMUNITY AND ALLERGY	
2.1 Native and adaptive immunity	8
2.2 The immune system	11
2.3 Antibodies	13
2.4 Cell-mediated immunity	17
2.5 Complement	18
2.6 Allergy	21
2.7 Allergic reactions	27
3 OCCUPATIONAL ALLERGY	
3.1 Allergy and work	29
3.2 Respiratory allergy	30
3.3 Skin allergy	32
3.4 Allergy and the eye	33
3.5 Properties of allergens	34
3.6 Sources of occupational allergens	35
3.7 Diagnosis of occupational allergy	38
3.8 Common occupational allergens and their effects	40
4 STRUCTURAL BASIS OF ACTIVITY	
4.1 Functional groups	46
4.2 Bonding to protein	73
4.3 Conjugates	74
4.4 Active sites	81

CHAPTER	PAGE
5 ACID ANHYDRIDES	
5.1 Introduction	87
5.2 Respiratory sensitisation	88
5.3 Antigenic determinant	96
5.4 Reaction mechanisms	99
6 CONCLUSION AND RECOMMENDATIONS	
6.1 Summary of current data	102
6.2 Sensitisation	104
6.3 Control measures	107
6.4 Screening of workers	113
6.5 Availability of information	116
APPENDICES	
I TESTS USED IN ALLERGY INVESTIGATIONS	
a) Skin tests	119
b) Provocation tests	121
c) Respiratory function tests	124
d) Laboratory tests	129
II GLOSSARY	134
III REFERENCES AND BIBLIOGRAPHY	142

INTRODUCTION

The presence of diseases and disorders in workers developing from and specifically related to their occupations has been recognised for centuries. As early as Roman times there was some awareness of the connection between occupations and diseases particularly in relation to metal miners and sulphur workers. In the seventeenth century¹ Paracelsus a physician, identified the miner's liability to lung disorders and the smelter's risk of poisoning by heavy metals. Ramazzini, the father of occupational medicine, published a treatise in 1700 and² not only identified many occupational disorders but also suggested ways of avoiding or reducing them. Knowledge and awareness of conditions related to particular trades or industries has continued steadily up to the present.³

However, the potential for exposure to hazardous chemicals today is greater than ever before. not only in the working environment but also in the home and during recreational and other leisure activities. In the present century, and especially since the Second World War, the rapid development and diversity of industry have created a marked increase in the numbers of organic and inorganic substances that are toxic or have potential as allergens or irritants.

Recent literature on incidents of occupational allergy and information regarding case histories is fragmented and of variable quality. Statistics on the prevalence of particular conditions are difficult to obtain with any degree of accuracy. One reason for this is that unlike many other occupational diseases, allergy per se is not a notifiable condition under current health and safety legislation in this country.

The subject of sensitisation and occupational asthma was reviewed by the Industrial Injuries Advisory Council in 1981 when seven groups of agents were studied. Principally as a result of the Councils⁴ report occupational asthma was scheduled in March 1982 as a prescribed disease enabling workers suffering from permanent disablement caused by certain agents to claim industrial benefit⁵. Whilst only seven groups of agents are currently listed (see table 1) it is likely that further agents will be added in due course. Benefit is only available to workers suffering an irreversible condition and is not claimable in respect of short term disability. Accordingly only serious cases of the disease are reported and then only in retrospect. Furthermore occupational asthma can develop from non-allergic causes, especially through irritation, and it is such cases which are likely to be permanently disabling and therefore reported rather than those developing through allergy.

TABLE 1OCCUPATIONAL ASTHMA

Prescribed causal agents under the Industrial Injuries Scheme.⁵

Isocyanates

Platinum salts

Acid anhydride and amine hardening agents (used in epoxy resin systems)

Fumes arising from use of rosin as soldering flux

Proteolytic enzymes

Dusts arising from barley, oats, rye, wheat or maize or meal or flour made from such grain


Animals or insects (used in research, education and laboratories etc)

The Industrial Injuries Advisory Council is currently reviewing the data on other known sensitisers with a view to extending the list of prescribed causal agents for which injury benefit can be claimed by chronic sufferers.

Much of the published data on occupational allergy (and respiratory allergy in particular) is derived from case histories of individual workers referred to specialists for diagnosis and treatment. Some surveys and epidemiological studies of groups of workers and whole industrial plants have been undertaken. A variety of study options have been used including both cross sectional and longitudinal, retrospective, prospective and specific groupings. (See figure 1). Limited studies on animals particularly the guinea pig have also been undertaken. In many cases strong immunological evidence of an allergic mechanism causing symptoms in workers suffering adverse reactions to substances at work has been obtained but in others an allergic involvement can only be deduced or suspected. Clearly this reduces the reliability of the data when taken out of context.

The manner in which the respiratory sensitisation problem has surfaced in different occupations has varied considerably. Farmer's lung, Malt worker's lung and allergies in workers handling animals have been recognised for some time. The causal agents are known to be proteins or other macromolecules present in moulds and other fungi growing on hay or barley and in the latter case, arising from animal waste products (dander).

FIGURE 1

STUDY OPTIONS IN OCCUPATIONAL EPIDEMIOLOGY⁷

Traditionally emphasis has been given to diseases and disorders (eg. asphyxia, burns, poisoning etc.) resulting from acute exposure to fairly high concentrations of such substances and the physical problems (eg. fire and explosion risk) presented by them. More recently concern has been directed towards more long term conditions (including asthma and various forms of cancer) likely to be caused by continued exposure to lower concentrations. Indeed routine toxicity testing involving animals has become established practice and is mandatory in certain cases.

The problem of occupational allergy however, remains relatively obscure and masked to a large extent by these 'more important' considerations. The limitations of current data, inability to establish unequivocal diagnosis in apparently sensitised patients, the low concentrations of chemicals involved and the small numbers of workers likely to be affected often mean that little priority is given to this subject in many industries. The lack of established animal tests to screen chemicals for the existence of sensitising effects on humans together with problems of identifying highly susceptible workers prior to exposure are additional factors. Dermatitis (which may be allergy related in some cases) is somewhat of an exception with positive steps being taken in most factories to eliminate or reduce incidents amongst exposed workers, although such precautions are often introduced for different reasons and prevention of dermatitis is a secondary consideration.

One of the first instances in industry was the sensitisation of workers involved in enzyme detergent manufacture which was also linked with skin problems amongst workers and consumers using these products.⁸ Most recent attention has focused on a wide range of organic isocyanate materials used in industry. In the printing and packaging trades where isocyanate containing inks and adhesives have been widely used trade union pressure has led to substitution of many of these products. currently similar concern is being expressed over the use of isocyanates in the production of polyurethane foam and the spraying of polyurethane paints Allergy to inorganic compounds particularly platinum salts is also well established with 20-25% of the workforce in one U.K. plant alone known to suffer from the condition.⁹ Workers in the pharmaceutical and animal feed industries are also high on the list of occupational allergy sufferers.

This dissertation is primarily concerned with respiratory allergies and other adverse reactions in man arising from substances released into the environment in industrial (and other occupational) processes focussing in particular on the molecular basis of such reactions. The substances concerned are principally reactive organic chemicals of relatively low molecular weight present in dusts, gases and vapours in working environments as a consequence of particular industrial or related processes. The adverse effects of inorganic chemicals, drugs/administered for therapeutic purposes/and of living organisms have been specifically excluded from this study.

IMMUNITY AND ALLERGY

2.1 Native and adaptive immunity

Immunity refers to the capacity enjoyed by an organism to remain unaffected by harmful agents in its environment and from those arising from within itself. The defence mechanisms responsible for this immunity are understandably complex and varied but two broad classifications are recognised:

- a) Non-specific or native immunity - general body defences which kill or prevent the multiplication of micro-organisms or other parasites.
- b) Specific or adaptive immunity - mechanisms that are activated individually after a microbe or other foreign material invades the body.

Native immunity is provided by several routes including the physical barriers of the skin and membranes and the filtering of nasal passages. Bacteriocidal enzymes in saliva, acidic substances in the stomach and chemical agents in the blood (eg properdin) and other tissue fluids capable of ^{equally} inhibiting or destroying microorganisms are all/important. In addition all higher animals contain scavenging cells which ingest and destroy foreign particles. These are principally of two types, namely macrophages and granulocytes (polymorphonuclear leucocytes) both of which originate from cells in the bone marrow.

Granulocytes are highly motile cells containing granules (packets of powerful digestive enzymes and bactericidal agents) and are attracted by chemotactic agents and migrate to foreign material including bacteria which they ingest and digest. Macrophages also efficiently ingest foreign particles and digest bacteria but are slower moving than granulocytes.

A third type of cell (Eosinophils) which also originate from the bone marrow, have a phagocytic potential although their function is largely unknown. They accumulate at sites of antigen-antibody reaction in response to specific chemotactic factors liberated locally. Immune reactions involving IgE are particularly prone to attract eosinophils.¹⁰ They are also implicated in the processing and cell to cell transfer of antigen breakdown products. In parasitic infections an increase in the number of blood eosinophils usually occurs.

A fundamental property of adaptive immunity is a highly specific memory, since the system actually learns from first interaction with a given agent. Furthermore the system has the ability to recognise materials that are foreign ie. to distinguish self from non-self. A remarkable and economical feature of the immune system is that recognition leads by one or more processes to inactivation.

Materials which can give rise to specific immune responses and interact with the cells and/or antibodies produced are termed antigens. Some foreign materials (generally of low molecular weight) are able to interact

specifically with pre-existing cells and/or antibodies but require to be conjugated with another material, usually protein, before being able to elicit a specific immune response themselves - these are known as haptens. In these cases it is the chemical reactivity of the molecule which is important not its size.

Recognition of a material as self occurs as a result of the material being present (at a suitable concentration) during the prenatal development of the organism. Additionally for material to be regarded as self it must be accessible to the cells of the immune system during development. The immune system of an organism will generally not respond against material regarded as self. This self-tolerance is achieved, during foetal development, by the removal or inactivation of certain cells of the immune system capable of reacting against the antigens of the body.

Tolerance to foreign antigens can also be achieved after birth through the administration of very small amounts of antigen repeatedly over a period of weeks or the administration of large amounts over a shorter period of time. The given antigen must be present in a form which allows it to persist in the circulation and not all be taken up by macrophages and related processes. The maintenance of tolerance must be a continuous process since the active principles of specific immunity are constantly changing and new cells and/or antibodies reactive to the given tolerated antigen may evolve which would initiate an immune response against it unless they are inactivated.

Most antigens have several distinct areas on their surfaces which are recognised as foreign and give rise to the specific responses against them, these areas are known as antigenic determinants. When two different antigens have one common antigenic determinant some of the antibody response made against one antigen will be able to react with the other, such antigens are known as cross-reacting antigens.

2.2 The Immune System and Specific Immunity

The immune response in specific immunity centres around a family of white blood cells called lymphocytes. In adult animals lymphocytes are derived from stem cells which are continuously formed in the bone marrow; these stem cells pass in the bloodstream from the bone marrow to specialist tissues known as lymphoid organs, eg. the thymus gland, spleen, tonsils, appendix, lymphnodes etc. The life cycle and behaviour of lymphocytes depends upon the location of the stem cells from which they originate, ie. whether they migrate from the bone marrow into the thymus gland or into other lymphoid tissues. Although all lymphocytes are similar in appearance they acquire characteristic components in surface membranes and differences in behaviour depending on the lymphoid tissues to which they relate.


(See figure 2.)

The immune system can be regarded as two parts, humoral (antibody mediated) immunity and cell-mediated immunity, although there is interaction between the two systems in various immune responses. The two arms of the immune

FIGURE 2

DIFFERENTIATION OF LYMPHOCYTES¹¹

A SCHEMATIC DIAGRAM OF THE FORMATION OF LYMPHOCYTES FROM BONE MARROW STEM CELLS AND THEIR DIFFERENTIATION INTO VARIOUS TYPES OF CELL INVOLVED IN THE IMMUNE RESPONSE.



system were discovered through experiments which tested:

- i) whether a particular sort of immune response occurring in an individual could be transferred to a previously unimmunised individual by serum taken from the former and separated from his blood cells,
- or ii) whether the reactivity could be transferred by the cells in the absence of serum.


Such experiments have made it possible to characterise many features of the two arms of the adaptive immune response in isolation from each other.

2.3 Antibodies

Humoral immunity is the arm based on soluble serum factors. Although there are many different reactivities in this category they have one prime feature in common - their specificity for particular foreign materials is dependant on specific antibody. For this reason reactivities within this area are termed antibody-directed immunity. Humoral antibody, namely the four principal types of immunoglobulins (referred to as IgA, IgE, IgG and IgM) are manufactured by cells of the B-cell system. (IgD is also produced but its role is not understood.) (See figure 3).

The clonal selection theory of antibody formation¹² (See figure 4) was developed in the 1950's by Burnet based on the selective hypothesis of Jerne. Circulating small B-lymphocytes carry highly specific receptors on their surface. Antigen selects from this preexisting array of cells and those

FIGURE 3

THE STRUCTURE OF IMMUNOGLOBULINS - THE ANTIBODY MOLECULE

IMMUNOGLOBULIN G (IgG)
(molecular weight approx 150,000)


(IgM) IMMUNOGLOBULIN M
(mol. weight approx 1,000,000)

(IgD and IgE are similar to IgG in general structure; but have large H chains.)

IgA is composed of multiples of the basic unit, often a dimer)

The H and L chains are glycoproteins.

FIGURE 3b. DIAGRAM OF THE IgG MOLECULE SHOWING THE LOCATION OF LOOPS (DOMAINS) IN THE PROTEIN BACKBONE



domain regions:

V_H variable heavy

V_L variable light


C_H^1 constant heavy 1

C_H^2 constant heavy 2

C_H^3 constant heavy 3

C_L constant light

FIGURE 4.

ANTIBODY PRODUCTION - THE CLONAL SELECTION THEORY

having specific receptors to it are stimulated to divide and produce a clone of daughter cells. Some of these progeny are memory cells whilst others develop and mature into plasma cells, which have a particular ability to produce antibody at a high rate. The presence of memory cells enables a subsequent challenge with the same antigen to invoke a greater response than the previous encounter.

The commonest type of immunoglobulin (IgG) is distributed throughout the body in both the blood and tissue fluids and / certain sub-classes are able to cross the placenta, thereby conferring immunity on the foetus. IgG is capable of activating complement and of initiating complement fixation (see below). IgM, a much larger molecule than IgG is found principally intravascular and is able to achieve greater complement activation than IgG. IgA is the principal immunoglobulin found in tears, milk, sweat, saliva and mucous secretions. It is found in the lining of the respiratory tract and the gut where it is capable of surviving hydrolytic conditions for significant periods. The fourth main type, (IgE) often referred to as reaginic antibody, is involved in immediate type allergic reactions. It has the ability to bind to the surface of mast cells¹³ and induce the release of histamine and other pharmacologic mediators from these cells following antigen binding.

Antibody can affect antigen in three ways (See figure 5):-

- a) Direct binding of the antigen by antibody
(especially where the antigen is a virus or bacterial toxin) neutralises it and interferes

with its proliferation, movement and ability to attack other cells in the body- a process known as agglutination if the antigen is particulate.

b) Binding of antibody to antigen in the presence of complement (see later) enhances the lysis of cellular antigen and also facilitates phagocytosis by scavenging cells.

c) By directing and influencing the activity of certain cells in association with the binding of antibody to antigen. Specific antibody with receptors for macrophages or neutrophils may bind to antigen giving rise to enhanced phagocytosis of the antigen by the cell or in the case of cellular antigen to killer cell activity (ie) the target cell is directly killed by the macrophage or lymphocyte by means of a mechanism not presently understood.

Antibody may also bind to mast cells or basophils prior to binding with antigen resulting in the release of pharmacologic mediators from the cells when binding to antigen takes place. This latter¹⁴ mechanism is a key part of immediate type hypersensitivity.

2.4 Cell-mediated Immunity

Cell mediated (or cellular) immunity is the part of specific immunity where the reactivities are wholly a feature of the cells themselves in that they can be carried out in the absence of soluble antibody, and the specificity is directed by the actual cells. The small lymphocytes involved

are influenced by the foetal thymus either by contact with epithelial cells or by a diffusible substance elaborated by the thymus, or perhaps both, causing them to differentiate into various kinds of thymic lymphocytes (T-cells). (See figure 2). This normal response is important for normal protective mechanisms against specific organisms such as viruses, fungi, parasites and certain bacteria.

T-cells can affect antigen by three main routes (See figure 5) (probably only one effect is possible by any individual T-cell) namely:-

- i) Direct attack on the antigen (target cell) - the killer cell effect.
- ii) The elaboration of various factors which have a direct effect on the antigen.
- iii) The production of lymphokines - factors which attract other cells by chemotaxis and influence them to attack the particular antigen.

2.5 Complement

Complement comprises a system made up of nine distinct components (all proteins) which are present in the blood and tissue fluid of animals. The complement system constitutes a sequence of trigger mechanisms well suited to enlarge and diversify the effects of an antigen-antibody reaction. One of the important properties of complement is its ability to cause lysis of sensitised cells (ie. cells which have bound antibody) especially bacteria, through disruption of the cell membrane. (See figure 6).

FIGURE 5.

SUMMARY OF IMMUNE REACTIONS TRIGGERED BY ANTIGEN AND THEIR EFFECTS






FIGURE 6.

THE COMPLEMENT PATHWAY : A CASCADE SYSTEM

A SYSTEM OF REACTIONS INVOLVING PROTEINS AND COFACTORS TRIGGERED
FOLLOWING CERTAIN ANTIGEN/ANTIBODY REACTIONS AND WHICH
RISE TO MANY OBSERVABLE BIOLOGICAL EFFECTS. THERE IS A LARGE
ELEMENT OF AMPLIFICATION IN THE PATHWAY.



CLASSICAL PATHWAY OF COMPLEMENT ACTIVATION



ALTERNATIVE PATHWAY OF COMPLEMENT ACTIVATION

The bar above the complexes indicates enzymic activity.

C_{3a} is an anaphylatoxin C_{4a} is an anaphylatoxin C_{5a} is an anaphylatoxin and a chemotactic factor

Other important actions of the system include release of anaphylatoxin, a poly peptide, which initiates local muscle contraction and vasodilation (an anaphylactic type response); enhancement of immune adherence to cells (which facilitates ready ingestion and which attracts granulocytes to migrate to the site of the complex) and the stimulation of lymphokine production by lymphocytes.

2.6 Allergy

These systems which are normally immunoprotective can also be involved in immunopathologic processes where the system gets turned on and does not protect but is actually detrimental to the host. Four broad types of adverse reaction are recognised and are generally referred to as type I, II, III or IV according to a classification put forward by Gell and Coombes in 1968.¹⁵ (See table 2.)

The humoral antibody system is involved in three types of immunopathological reaction ie. types I - III reactions. In type IV or cell-mediated disease the T-cell system or cellular immune system is responsible for the reactions. Types I, III and IV reactions (which may be present in the subject at the same time) may be demonstrated by skin tests. While type II allergy has a skin presentation it is not looked for in normal routine skin testing.

The term Allergy (an altered capacity to react) was introduced in 1906 by von Pirquet and applied to specifically induced reactions which were either enhanced or depressed.¹⁶ The word is nowadays used to mean altered reactivity which is increased above normal in response to an external

TABLE 2 : TYPES OF ALLERGIC REACTION - THE GELL AND COOMBS CLASSIFICATION.¹⁵

GELL AND COOMBS CLASS	I	II	III	IV
SYNONYMOUS DESCRIPTIVE TERMS	ANAPHYLACTIC OR IMMEDIATE HYPERSENSITIVITY	CYTOTOXIC	ARTHUS OR IMMUNE COMPLEX	CELL-MEDIATED IMMUNITY OR DELAYED HYPERSENSITIVITY
PRIMARY LYMPHOCYTE INVOLVED	B	B	B	T
OTHER CELLS INVOLVED	MAST (BASOPHIL) CELLS AND EOSINOPHILS	POLYMORPHONUCLEAR CELLS		LYMPHOCYTES AND MACROPHAGES
IMMUNOGLOBULIN INVOLVED	IgE poss IgG	IgG, IgM	IgG, IgM	NONE
COMPLEMENT INVOLVED	NO	YES	YES	NO
EXAMPLE OF ANTIGEN	GRASS POLLEN; CONJUGATES OF PENICILLIN WITH CERTAIN PROTEINS	CIRCULATION SURFACE ANTIGENS	THERMOPHILIC ACTINOMYCES	TUBERCULIN PROTEIN p-DINITRO CHLOROBENZENE OTHER REACTIVE CHEMICALS
TIME SCALE	20 MIN	-	6 - 8 HRS	24 - 48 HRS
SKIN TESTING TYPE OF REACTION WITH CELLS INVOLVED	WHEEL & FLARE MAST CELL OR BASOPHIL	NOT DONE	ERYTHEMA & INDURATION (ARTHUS REACTION)	ERYTHEMA & INDURATION MONONUCLEAR CELLS
IN VITRO TEST	R.A.S.T OR HISTAMINE RELEASE FROM LEUCOCYTES	CYTOLYSIS OF CELLS	PRECIPITIN REACTION	LYMPHOCYTE BLAST TRANSFORMATION BY ANTIGEN

noxious antigenic agent. Hypersensitivity, which implies a specifically increased capacity to react, is often used interchangeably with the term allergy. The antigenic agent which is capable of inducing a state of allergy in some persons is termed an Allergen.

An allergic reaction involves two (or more) contacts with the allergen:

- i) an initial encounter by the individual of the allergen in which no reaction is apparent but as a consequence of which he is sensitized,
- ii) a later encounter with the same material which triggers the allergic state causing a strong adverse reaction.

It is the process of sensitization which distinguishes allergy from irritation. Whilst the observed effect after encounter by a given allergen may be similar to that following encounter by an unrelated irritant the latter effect is not dependant on previous exposure of the individual to the substance concerned and does not involve the individual's immune system.

It is clear that many substances possess both antigenic and irritant properties and that the observed response following exposure to these substances results from several reactions. The physical, chemical and biological properties of the substance (especially its concentration), the route and other circumstances of exposure, together with the immunological reactivity and previous medical

history of the person exposed will influence the particular response observed.

The metabolism of a given substance by the individual concerned is an additional factor. The body generally treats foreign substances as undesirable materials which must be excreted as soon as possible. The chemical transformation of the substance by degradation or enzymic metabolism (including hydroxylation, conjugation, reduction or oxidation) to create a more polar (ie. more water soluble) compound or compounds and thereby facilitate excretion is primarily carried out in the liver. The metabolite or metabolites produced may be immunologically significant especially if they have an ability to react with proteins or other macromolecular structures. Obviously a supply of these susceptible carrier molecules is essential for the metabolites, acting as haptens to form antigens; however, proteins synthesised locally within the liver are ideally suited to combine with newly formed reactive metabolites.

The traditional criteria¹⁷ for regarding a reaction as allergic (with or without supporting immunologic evidence) are as follows :

- i) There is a history of previous exposure (without symptoms)- the period of sensitisation
- ii) The degree of specific sensitivity may increase with further exposure
- iii) A proportion, usually low, of exposed subjects are affected.

Generally allergic responses are elicited by dosages far less than those capable of sensitisation which in turn are usually far less than those capable of irritation. (See table 3). Furthermore allergic responses occur only in a small proportion of persons exposed to the substance at a given concentration whereas responses to irritation are more likely to affect most exposed subjects and all are unrelated to previous exposure.

Atopic individuals¹⁸ appear to have a genetically determined capacity to produce specific IgE antibodies readily in response to the immunologic challenge presented by the ordinary, usually limited, exposures in daily life to common allergens. They¹⁹⁻²¹ show a higher incidence and a far more rapid sensitisation to occupational agents than do non-atopic subjects.

An individual's immunological reactivity²² such as the affinity or avidity of antibodies produced and the capacity of complement to modify the solubility and handling of immune complexes may also have a bearing on responses. Affinity is the description of the interaction between a single antibody site and antigen (or hapten) - the higher the affinity of a given antibody the lower the concentration of antigen (or hapten) required to cause half of the antibody-binding sites to be occupied. Avidity relates to how well antibodies and antigens stick together and is dependant on additional features such as the number of binding sites the antibody molecule has for antigen and the number of determinants on the antigen.

TABLE 3EXAMPLES OF THERELATIVE QUANTITIES OF REACTIVE CHEMICALS INVOLVEDIN IRRITATION, ALLERGIC REACTIONS AND SENSITISATION.

Data for
Toluene diisocyanate fumes²³

Irritant	> 0.5ppm
Allergic	0.005 to 0.02 ppm

Data for
Platinum salts¹³⁶

Irritant	10^{-6} to 10^{-9} g
Allergic	10^{-15} g (approx 100,000 to 200,000 molecules)

2.7 Allergic Reactions

The response following reaction between allergens and sensitised cells is influenced by the particular mechanism triggered. The clinical manifestations observed in allergic reactions are not specific to the allergen involved.

In the immediate reaction (type I) IgE antibody bound to the surface of circulating basophils and to mast cells reacts with antigen and leads to structural changes in the cells (degranulation) and release of pharmacological mediators. These chemical messengers, in particular histamine and SRS-A (slow reacting substance of anaphylaxis) act directly on local tissues and organs such as the capillary network, blood vessels, secretory glands and nerve cells. Histamine causes vasodilation in vascular tissue and increased permeability to plasma proteins thereby leading to inflammation, and contraction of smooth muscle leading to bronchoconstriction. SRS-A also contracts smooth muscle. Other mediators including prostaglandins and bradykinin also have vascular effects. IgE would seem to be a very rapid method for mobilising defence mechanisms locally. It is unlikely that IgE has a significant role in any other way since the quantities apparently involved do not appear sufficient to neutralise or agglutinate antigen.

Type III allergic reactions involve circulating antibodies (primarily IgG) reacting with antigen in the blood stream forming immune complexes and activating the complement cascade. This in turn activates blood clotting mechanisms, liberates kinin and the release of proteolytic enzymes, permeability & chemotactic factors.

The involvement and role of mediators in late (type III) reactions has been less widely studied and is not fully understood. It is possible that some mediators could have pro-allergic or inflammatory effects in the immediate reaction but opposing effects in the late reaction (prostaglandins in particular show examples of this and appear to exert vascular effects at an early stage but effect cellular cAMP levels and other effects later.) Many cases of respiratory allergy in particular appear to involve both an immediate and a late reaction commonly referred to as a dual response.

The true delayed reaction (type IV) is mediated by cells of the T-cell system, through the mechanisms described in section 2.4. The tuberculin-type skin reaction as observed in patch testing with allergens is the commonest indication of a delayed type reaction mechanism. The response develops slowly and reaches a maximum at 24 to 48 hours.

There is however some evidence for a role for basophils and mast cells as well as serum antibodies in delayed responses.²⁴ Many delayed responses, including contact lesions, in animals and man are heavily infiltrated with basophils;²⁵ some delayed skin reactions can be blocked by inhibitors of vasoactive amines²⁴ (suggesting that mast cells or basophil mediators are involved in the pathology of the lesion) and contact sensitising agents can induce an antibody response including reaginic (IgE) antibodies.²⁶

OCCUPATIONAL ALLERGY

3.1 Allergy and Work

Since allergic reactions may be precipitated by non-occupational agents, (just as all adverse effects of an occupational agent may not involve sensitisation), in view of the long latent period of exposure (over ten years in many cases) and the likelihood that other workers are not affected, the basic causal agents may go unsuspected and domestic or recreational environments may be implicated instead. Bernadino Ramazzini (a professor of medicine in Italy in the eighteenth century) was the first to publish² a systematic account of trade diseases and highlighted the need to ask patients the important question 'What is your occupation?' when undertaking clinical investigations.

Improvement in or cessation of symptoms at weekends or during holidays or following changes in work locations or occupation generally indicate an occupational origin for the disease. Furthermore the rapid return of symptoms on resumption of work may suggest an allergic mechanism.

Allergic reactions caused by occupational agents giving rise to effects on the skin, the eyes or the respiratory tract have all been observed. Adverse reactions of the gastrointestinal tract also occur in food allergies, but are of little significance in occupational allergy. Whilst the observed reaction may indicate the organ or system in first contact with the agent this is not always the case (eg. respiratory disorders may result from general skin

contact with the agent or skin disease may follow from ^{27.30}ingestion).

3.2 Respiratory Allergy

Adverse reactions of the respiratory tract include allergic rhinitis (eg hay fever), asthma and extrinsic allergic alveolitis (referred to as hypersensitivity pneumonitis in N. American terminology.) Although rhinitis is fairly common in the general population it has little significance in occupational allergy.

Asthma,³¹ (defined as reversible obstruction of the bronchi and bronchioles) occurs in a wide variety of reactions

which fall into two main categories, as described below.

It can be caused by several factors unrelated to sensitisation including irritation. Immediate asthmatic reactions develop within minutes and can usually be associated with a particular causal agent. They rapidly reach a maximal effect and last about $1\frac{1}{2}$ to 2 hours. These reactions can be reversed by inhaled bronchodilator drugs and can also be blocked by the prior administration of sodium cromoglycate.

Corticosteroids do not block the reaction. A type I reaction mechanism is thought to be involved.

The other group are termed non-immediate asthmatic reactions since they develop slowly and often imperceptibly. The reaction may develop after 1 hour and last approximately 5 hours or may come on after several hours reaching a maximum effect at 5 to 8 hours and last up to 24 hours. They can be blocked by sodium cromoglycate and are also

effectively blocked by corticosteroids. However, they respond poorly to bronchodilators. In this case a type III reaction mechanism is thought to be involved. A further non-immediate reaction, recurrent nocturnal asthma, develops in the early hours of the morning following exposure and recurs without further exposure at the same time each night for several nights. This reaction responds poorly to all of the drugs.

The chief features of Extrinsic Allergic Alveolitis resemble a viral or bacterial infection.³² They include chills, fever, sweating, malaise, anorexia, nausea, headache, chest tightness, a non-productive cough and dyspnea without wheezing developing from 4 to 6 hours after exposure. The symptoms resolve spontaneously in 12 to 18 hours but will recur on reexposure. Farmer's lung and Bird fancier's lung are forms of extrinsic allergic alveolitis. There is a decrease in the forced vital capacity (FVC) and one second forced expired volume (FEV_1) of the lungs (See Appendix 1). Non atopic subjects usually exhibit this single stage response after short term exposure to the antigen to which they are sensitised. The reaction can be blocked by sodium cromoglycate but not by isoproterenol and can be improved by the use of corticosteroids.

A two stage reaction may be seen in atopic subjects. Immediately after exposure there is a typical asthmatic reaction (type I) which is followed by a late type III reaction developing from 4 to 6 hours afterwards.

In some cases of a dual type response although the FEV_1 decreases there is little change in FVC indicating that the physiological changes in the late phase are primarily obstructive involving the larger airways.

3.3 Skin Allergy

When the skin reacts adversely to the working environment it can do so in a variety of ways.³³ Its commonest reaction is to become inflamed, a condition known as dermatitis or eczema. Inflamed skin looks red, swollen, blistered, weeping, flaky or cracked. It usually itches.

The commonest causes of occupational dermatitis are chemical substances in contact with the surface of the skin. This contact dermatitis may be caused by direct physical damage through irritation ie. acids, alkalis and organic solvents. It may also be caused by sensitisation involving an allergic mechanism when the substance involved is referred to as a contact allergen or contact sensitiser. Many contact sensitisers do not feel harmful to the skin and their effect may take months or years to show. Dermatitis may also be caused by a phototoxic or photoallergic mechanism where the additional stimulus of sunlight or UV light is required in conjunction with the chemical agent.

Urticaria (blistering of the skin commonly seen in allergy to ivy or nettles) may also occur in occupational environments and be caused by allergic as well as non-allergic mechanisms.

Adverse reactions to ingested materials (eg. food allergies) are commonly manifest by way of urticarial responses.

Other skin reactions occur to particular chemicals found in the working environment eg. oil acne which looks similar to teenage spots but is caused by excessive exposure to mineral oil. (eg in machine workers in the engineering industry)

3.4 Allergy and the eye

The skin of the eyelids is susceptible to the same types of hypersensitivity disorders and infections which involve the skin of other parts of the body.³⁴ Erythematous and exudative lesions may occur with scaling and crusting in later stages.

The other principal site in the eye involved in adverse reactions is the conjunctiva (the membrane covering the front of the eye). Contact sensitisation may produce conjunctivitis (inflammation of the conjunctiva) characterised by a papillary response, pronounced vasodilation, oedema and watery discharge. Conjunctivitis is the chief ocular manifestation of many allergies to common airborne substances and is often seen in hay fever. A milky appearance and stringy exudate are characteristic of an allergic conjunctivitis in contrast to the brilliant red appearance and purulent exudate found with bacterial conjunctivitis.

Allergen in direct contact with the conjunctiva interacts with IgE bound to mast cells initiating the release of mediators (including histamine, slow reacting substance of anaphylaxis SRS-A, and phagocyte activating factor PAF) which affect local blood vessels, smooth muscle and secretory glands and give rise to the clinical manifestations observed.

3.5 Properties of Allergens

With regard to respiratory allergies several factors predispose individuals to sensitisation by a particular agent: The nature of the organic dust or gas, the degree of exposure, the immunologic status of the patient¹⁷ and whether they are smokers.³⁷⁻⁴⁰

The physical and chemical properties of a particulate or gaseous antigen determine its immunogenicity. The size of the particle determines whether it reaches the bronchioles and alveoli where reaction occurs.³⁵ Gases and volatile liquids will travel further than large particles. The solubility of the particle dictates whether it is absorbed by the lymphatics and blood vessels or phagocytosed by alveolar macrophages.

The intensity and duration of exposure are important aspects influencing the occurrence and the mode of presentation of the disease. A certain degree of exposure over a given time may give rise to tolerance in some individuals. Exposure at a high intensity is likely to precipitate irritant phenomena in most individuals which will probably mask

allergic effects even when exposure is reduced.

Differences in the immunologic status of patients clearly influences their likelihood of being sensitised. The reason for only a few individuals in a particular group of exposed workers becoming sensitised to a given agent is not understood. The reactivity of the individual is clearly different and this may stem from a variety of reasons including genetic factors. The concept of atopy^{18:36} is part of this. Evidence suggests that most workers exposed to a particular chemical are likely to develop antibodies to it without becoming sensitised. The elicitation of a type III response to a particular antigen by some individuals in contrast to others developing a type I or dual response further illustrates this difference.

3.6 Sources of Occupational Allergens

Even in occupational environments sensitising agents arise from animal or vegetable sources (including micro-organisms) or from non-living (industrial) chemicals. (see table 4.) In the case of living or dead animal matter and with fungi and bacteria the allergens are generally proteins (including

TABLE 4 : OCCUPATIONAL ALLERGENS

SUBSTANCES REPORTED AS GIVING RISE TO CASES OF SENSITISATION
TO WORKERS IN VARIOUS OCCUPATIONAL ENVIRONMENTS.

ANIMAL SOURCES

Animal dander - hair, epidermal squamae,
urine, faeces⁴²⁻⁴⁹
Arthropods⁵⁰⁻⁶²

VEGETABLE SOURCES

Flour dust⁶³⁻⁶⁶
Cotton seed^{67;68}
Castor bean^{69;70}
Grain dust^{62;71}
Garlic⁷²⁻⁷⁴
Gums⁷⁵
Soybean dust⁷⁶
Western Red Cedar wood dust⁷⁷⁻⁸⁴
Other wood dusts⁸⁵⁻⁹²
Colophony resin⁹³⁻¹⁰⁰
Papain¹⁰¹⁻¹⁰³
Coffee bean¹⁰⁴⁻¹⁰⁶
Henna^{107;108}
Mushrooms¹⁰⁹
Bromelain (from pineapple)¹¹⁰⁻¹¹¹
Flax seed^{112;113}
Hemp^{112;113}
Maiko¹¹³

TABLE 4 CONTINUED : OCCUPATIONAL ALLERGENS

MICRO-ORGANISM SOURCES

Spores of thermophillic and other actinomycetes^{114; 115 - 118}
 Spores of other fungi — especially *Aspergillus* spp.^{119 - 124}
 Enzymes of *Bacillus subtilis* (used in detergents)^{8; 125 - 131}
 Antibiotics derived from *Penicillium* spp.^{132 - 133}

NON-LIVING (INDUSTRIAL) SOURCES

Platinum salts^{21; 134 - 138}
 Chromate salts¹³⁹
 Nickel salts¹⁴⁰
 Phenyl mercuric compounds¹⁴¹
 Synthetic fibres¹⁴²
 Persulphate salts¹⁰⁸
 Epoxy resin systems^{37; 143 - 153}
 Isocyanates^{154 - 171}
 Acrylates^{172 - 175}
 Reactive dyes^{176 - 179, 333}
 Other reactive organic chemicals (See Tables 5 to 9)

enzymes) or macromolecules. Inorganic (mineral) or simple organic chemicals found in industrial or other occupational environments are increasingly being implicated as sensitising reagents.

Ultimately the chemical nature of the agents is important rather than its source. The causal agents of allergic reactions due to wood dust and pine resins have been identified as simple organic chemicals.⁴¹ Obviously in the case of animal matter, micro-organisms, spores etc. several proteins and other chemicals intimately combined may be involved as the causal agent making extraction and identification of individual chemicals extremely difficult.

3.7 Diagnosis of Occupational Allergy

Identifying the causal agent and establishing the aetiology of a disease may be difficult but defining its pathogenesis (ie. the actual development of the disease) can be very involved and apparently impossible yet this must be achieved in order to promote successful treatment of patients and in prevention of further cases of the disease.

To ascertain a proper diagnosis of a disease involves not only detailed questioning and clinical examination of the patient but also appropriate physical testing (lung function, bronchial provocation and skin tests) and immunological investigations. (Appendix I summarises test procedures.)

Bronchial provocation tests in asthma and allergic alveolitis are a pragmatic means of aetiologic diagnosis that, at the same time, reproduce some or all of the clinical manifestations. In this respect the test reactions provide models of the clinical disorder and are useful in trying to interpret the variable history, in particular of clinical asthma.

By delivering controlled amounts of the suspected offending material either by aerosol nebuliser and face mask or by inhalation of vapour in a closed environment, or as a dust diluted in lactose powder, one can repeatedly determine respiratory function and obtain valuable information about patterns of bronchial reactivity as well as the effect of therapeutic agents. Unfortunately bronchoprovocation challenge testing affords little useful information concerning underlying immunological or non-immunological mechanisms.

The use of various treatment drugs in connection with provocation challenge testing provides some additional information as to the aetiology and pathogenesis of a particular disease.

Experimental, challenge-induced, immediate asthma readily responds to treatment with beta adrenergic stimulants such as iso-proterenol but not to inhaled or systemic corticosteroids. On the other hand, late asthmatic reactions due to occupational agents characterised by an interval of one to two hours between exposure and onset of

respiratory symptoms and prolonged asthmatic response can be inhibited by corticosteroids such as beclomethasone dipropionate.¹⁸¹ These late reactions also respond partially but poorly to beta-adrenergic stimulants. In other cases when dual, early and late asthmatic reactions occur both the immediate and late components can be prevented by prior administration of sodium cromoglycate some minutes before bronchial challenge.¹⁸² This drug, which was originally shown to protect a sensitised subject against an asthmatic reaction induced by the inhalation of house dust extract appears to inhibit the release of pharmacological mediators in man but apparently does not prevent antigen-antibody interaction.

3.8 Common Occupational Allergens and Their Effects

The following paragraphs in this section summarise the observed effects of some of the organic chemicals which are common occupational allergens and of the substances containing them. More detailed information on the effects of particular chemicals identified as causal allergens is contained in Tables 5 to 9 arranged according to the structure of the molecule concerned.

Allergic responses to epoxy resin or its constituents have been widely reported. Epoxy resin systems are amongst the most important causes of industrial contact dermatitis.

The uncured resin is the commonest cause but curing agents and even the cured resin may cause dermatitis. Cases of adverse respiratory symptoms have also been documented.

146:149:151:183-187

37:144:145:147:148:150:152:153

Epoxy resin systems have two basic components, the uncured resin and a curing agent or hardener. The resins vary in composition but all are long chain polymers commonly produced as condensation products of epichlorohydrin and bisphenol A and they vary from low viscosity liquids to solids depending on molecular weight. The resins are relatively stable in themselves but contain terminal reactive epoxy groups and side chain hydroxyl groups. The resins are converted to hard solids by the addition of a curing agent or hardener. In some systems external heat is necessary and these commonly use acid anhydrides as curing agents while others are cold curing, notably those using amine compounds. In either case curing of the resin is brought about by chemical splitting of the epoxy ring leading to cross linkages between the long chain resin molecules producing macromolecular three dimensional structures. During the curing process fumes of resin and curing agents are emitted.

It seems likely that the pulmonary hypersensitivity reactions result from the presence of curing agents such as polyamines (diethylenetriamine, triethylenetetramine, piperazine) or acid anhydrides (phthalic anhydride) rather than the polymer³⁷ itself.

The sensitisation by anhydrides is discussed in detail in Chapter 5.

Investigations of the allergenicity of epoxy resins and the sensitising capacity of their constituents using guinea pigs ^{188 - 192} has shown that epoxy resins of low molecular weight (340 daltons) is a potent sensitiser in these animals and that the sensitising capacity decreases in inverse proportion to the increase in average molecular weight of the resin mixtures.

Isocyanates are widely used in industry for the production of several products including polyurethane foams and are known to have toxic effects. They are mild skin irritants and sensitisation of the skin ^{193 - 195} can occur. In sufficiently high concentrations isocyanates have a primarily irritant ^{196 - 198} effect on the respiratory tract causing dry throat and coughing. Asthmatic attacks may result and may occur immediately on exposure or some hours ^{199 - 201} later. Some workers (about 5% of exposed persons) may become sensitised.

The two most common compounds are toluene di-isocyanate (TDI) and diphenyl methane di-isocyanate (MDI). Immediate, non-immediate and dual reactions to TDI have been observed and it has been shown ^{171:202:204 - 206} to induce recurrent nocturnal asthma.

The use of ultra violet cured inks has given rise ^{179:207 - 217} to allergic reactions in exposed workers. The ink usually consists of one or more conventional pigments dispersed in a polymeric vehicle. Included in this vehicle are polyfunctional acrylate monomers such as trimethylol propane triacrylate (TMPTA), pentaerythritol triacrylate

(PETA) and hexanediol diacrylate alone or in combination with monofunctional acrylic monomers such as hydroxyethyl acrylate or 2 - ethyl hexyl acrylate. Other constituents include UV reactive unsaturated polymers (often also acrylated materials), photoinitiators (eg. benzophenone), diluents (alcohols or phthalates), hydrogen transfer agents (eg. triethanolamine) and miscellaneous additives (including stabilisers, surfactants etc.) The UV radiation is absorbed by the photoinitiators resulting in the generation of free radicals which in turn cause polymerisation of the resin in which the pigments are incorporated and thus cures the ink film.

TMPA and PETA are known to be strong allergens and cross reactivity between them and other acrylates has been demonstrated.²¹⁹ The principal symptom is an erythematous pruritic rash and since its distribution on affected workers generally includes the face and neck as well as the hands and arms, it is suggested that airborne materials play an important role in eliciting the reaction.

Allergic contact sensitisation to several monofunctional acrylic monomers has also been widely reported,^{215-222;417} with methyl methacrylate most frequently incriminated although acrylonitrile acrylamide, ethyl hexyl acrylate and N tert butyl maleamic acid have been cited.

Resins used in the Letterflex printing process, which also uses UV light to trigger polymerisation,²²³⁻²²⁶ are reported as allergens.

However a polythiol (commonly pentaerythritol tetrakis 3 mercapto propionate) seems to be the chemical responsible.

Two types of symptoms are known :-

- i) Skin lesions - some of an irritant pruriginous and erythematous nature appearing on uncovered parts of the body; others of an eczematous nature primarily affecting the hands.
- ii) General symptoms including various degrees of conjunctivitis and respiratory disturbances with sneezing and rhinorrhea or conversely, nasal obstruction, coughing, dyspnea, and true asthmatic attack.

Amines present in the rubber of tyres have been reported²²⁷⁻²³³ to cause allergic contact dermatitis in exposed workers. N-isopropyl-N phenyl paraphenylene diamine (IPPD) and related compounds in particular give rise to eczema characterised by distinctly vesicular lesions on the backs of hands and forearms. Some cross reactivity occurs.

Occupational asthma due to sensitivity to colophony fumes⁹³⁻¹⁰⁰ have been reported. Colophony, which has been used as a soldering flux since ancient times, is the residue left after turpentine has been distilled from pine resin. It consists largely of abietic and pimaric type resin acids, the exact composition depending on the source of the material.

The common symptoms are wheezing, breathlessness and cough; sputum, rhinitis and eye irritation have also been observed.

The wheeze and breathlessness generally persist after work in the evening. Bronchial provocation testing in sensitised workers⁹⁵ generally elicits both immediate and late asthmatic reactions. Colophony itself is also a potent skin sensitiser.
234-236:411:412

Asthma due to inhalation of wood dusts is generally an^{87:237} irritant phenomenon. However, asthma caused by occupational exposure to dust from Western Red Cedar has been reported⁷⁷⁻⁸⁴ and appears to be a respiratory allergy. The syndrome includes chest tightness, dry irritating cough and wheeze (becoming worse at the end of the day) followed by nocturnal cough and wheezing. Nocturnal symptoms often persist for several days after cessation of exposure.⁴¹⁴ A type 1 reaction is thought to be involved and the principle allergen (hapten)⁴¹ has been identified as plicatic acid.

Cases of other wood dusts acting as respiratory allergens have been reported⁸⁵⁻⁹² and many woods are known to be contact sensitisers.
87:88:238-243:413

STRUCTURAL BASIS OF ACTIVITY

4.1 Functional Groups

Whilst physical factors (eg. particle size, solubility, volatility etc.).. concentration and route of 'invasion' of the causal agent are important, structure and molecular configuration are the key factors which affect the elicitation of a particular response. Indeed, since all biological activities are primarily effected by chemical means, the interaction between molecules (or more precisely between functional groups present on the molecules) is an essential precursor of the observed response.

At the molecular level, chemical reactivity is determined by the presence of particular functional groups and their relative accessibility. The accessibility of a given functional group present on the molecule is a consequence of its three-dimensional structure which determines whether it is inhibited from exerting an appreciable affect by the location of other atoms or groups (steric hindrance) or remains free to react with other molecules. The greater the complexity of the molecule the more likely it is that certain groups will be prevented from acting. Conversely and more importantly in such molecules two or more functional groups are likely to be brought together on the surface of the molecule forming an 'active site'. this is

particularly relevant in the case of proteins and other macromolecular substances and indeed constitutes the very basis of enzyme action.

Clearly the chemical composition and structure ultimately determines the three-dimensional configuration of the molecule. With small molecules the active functional groups are easier to determine but when conjugates are formed (eg. between haptens and carrier proteins) the reactivity of the resulting complex will be influenced not only by the remaining accessible groups of the smaller molecule but also by the groups of the larger molecule in close proximity to it.

Key functional groups present on molecules of substances which have given rise to allergic and other adverse reactions in man (or experimental animals) include the carbonyl-, amino-, and amido- groups as well as the presence of unsaturated centres in certain molecules. Obviously the close proximity of other groups to these key groups, either linked chemically or simply by position, will modify the reactivity of the key group.

Tables 5 to 9 summarise the observed symptoms of adverse reactions in humans (and in animal studies) following occupational exposure to particular organic chemicals containing one or more of these key functional groups. Adverse reactions which have not been shown to involve sensitisation (either by direct immunological evidence or by implication following the usual criteria) have not

TABLES 5 TO 9A SUMMARY OF THE OBSERVED REACTIONS TO, AND THE EFFECTS
OF, SMALL MOLECULAR WEIGHT ORGANIC CHEMICALS PRESENT IN
CERTAIN INDUSTRIAL AND RELATED WORKING ENVIRONMENTS.

TABLE 5: CARBONYL COMPOUNDS	PAGE NO.
5a Aldehydes	49-50
5b Quinones	51-53
5c Carboxylic acids	54-55
5d Acyl halides	56
5e Amides	58
TABLE 6: UNSATURATED COMPOUNDS	
6a Acrylates	59-60
6b Methacrylates	61
6c Acrylamides	62
6d Isocyanates	63-64
6e Reactive dyes	65-66
TABLE 7: COMPOUNDS CONTAINING STRAINED RING SYSTEMS	
7a Epoxides	67
7b Imides	68
TABLE 8: AMINES	69-71
TABLE 9: THIOLS	72

Structural Formulae, Index number, Solubility and Physical

Data from the Merck Index 10th Edition 1983.²⁴⁴

Long Term Exposure Limits (LTEL), Short Term Exposure Limits

(STEL) from Guidance Note EH 40 (Health and Safety Executive).²⁴⁵





TABLE 5a ALDEHYDES				
CHEMICAL	FORMULA	SYMPTOMS (WITH REFERENCES)	REMARKS	
FORMALDEHYDE (4093 gas) (4095 soln.)		²⁴⁶⁻²⁵⁶ ASTHMA (late reaction) EXTRINSIC ALLERGIC ALVEOLITIS ²⁵⁷ DERMATITIS ²⁵⁸⁻²⁷⁹	STEL ² LT _{EL} 2ppm; 3mg/m ³ widely used: disinfectant, preservative, formaldehyde resins, tanning agent, dye improver, photographic processing, paper making	
GLUTARALDEHYDE b.pt 187°		DERMATITIS ²⁸⁰⁻²⁸⁶	STEL ² LT _{EL} 0.2ppm; 0.7mg/m ³ antiperspirant, sterilising fluid, tanning agent capable of cross linking proteins and thereby forming new antigenic site by this mechanism	
GLYCIDALDEHYDE (2,3 epoxypinal)		DERMATITIS ²⁸⁷	skin irritant reacts with primary amino groups of proteins	
FURFURAL (4155) b.pt 161.8° colourless oily liquid volatile in steam soluble in water		²⁸⁸ ASTHMA (late reaction) DERMATITIS ²⁸⁷	STEL 15ppm; 60mg/m ³ LT _{EL} 5ppm; 20mg/m ³ used in the manufacture of furan resins	


TABLE 5a (continued) ALDEHYDES				
CHEMICAL	FORMULA	SYMPTOMS (WITH REFERENCES)	REMARKS	
ACROLEIN (123) (acrylic aldehyde) b.pt 52.5° unstable - polymerises	$\text{CH}_2=\text{CH}.\overset{\text{O}}{\underset{\text{H}}{\text{C}}}.\text{H}$	ASTHMA ²⁴⁴ (high concentration causes pulmonary oedema) DERMATITIS ²⁸⁷	LTEL 0.1ppm; 0.25mg/m ³ STEL 0.3ppm; 0.8mg/m ³ irritant to eyes and mucosa vapours cause lacrimation	
CINNAMALDEHYDE b.pt 246° slightly soluble in water	$\text{CH}=\text{CH}.\text{CHO}$ 	DERMATITIS ²⁸⁹⁻²⁹¹	found in cinnamon readily reacts with amines	





TABLE 5b QUINONES				
CHEMICAL	FORMULA	SYMPTOMS (WITH REFERENCES)	REMARKS	
6-METHOXY-2-METHYL-3,5 DIHYDRO BENZO (b) FURANO 4,7 DIONE		DERMATITIS ²⁹²	present in Australian blackwood	
2-DIMETHYL ALLYL 1,4 BENZOQUINONE		DERMATITIS ²⁹³		
1,4 BIS (ISOPROPYL AMINO) ANTHRAQUINONE		DERMATITIS ²⁹⁴	present in felt tip pen ink	
1,8 DIHYDROXY ANTHRAQUINONE (Danthron) (2802) m.pt 193-197° sublimes orange needles almost insoluble in water		DERMATITIS (photocontact) ²⁹⁵	dye	





TABLE 5b (continued) QUINONES				
CHEMICAL	FORMULA	SYMPTOMS (WITH REFERENCES)	REMARKS	
2,6-DIMETHOXY-1,4-BENZOQUINONE (3212) golden yellow prisms m.pt 256 sublimes volatile with steam		DERMATITIS ²⁹²	present in Australian blackwood	
R-4 METHOXY DALBERG IONE		DERMATITIS ^{238:241:242}	allergen in rosewood	
DITHIANONE (5,10-Dihydro-5,10-dioxonaptho(2,3,6)-1,4 dithin 2,3 dicarbo nitrile)		DERMATITIS ^{238:239}	present in henna	
DESOXYLAPACHOL		DERMATITIS ^{238:240}	principle sensitizer in teak wood also an irritant	



TABLE 5b (continued) QUINONES				
CHEMICAL	FORMULA	SYMPTOMS (WITH REFERENCES)	REMARKS	
MANSONONE A		DERMATITIS ²³⁸	present in <i>Mansonia</i> wood also an irritant	
NAPTHO FURANO QUINONES		DERMATITIS ⁸⁸	allergen present in wood of <u>peroba do campos</u>	

TABLE 5c CARBOXYLIC ACIDS





CHEMICAL	FORMULA	SYMPTOMS (WITH REFERENCES)	REMARKS
ETHYLENE DIAMINE TETRA ACETATE (3476) (Edetic acid or EDTA) soluble in water at 25°		DERMATITIS 297-299	chelates metals, could react in chemical configuration of protein which carries ions especially metal cations used in the cosmetic industry
PLICATIC ACID		ASTHMA (immediate, late and dual reactions) 77:79-83 RHINITIS 77:82	active principle in Western Red Cedar wood complement involved in the allergic reaction ³⁰⁰ may react as a phenol compound
CHLOROGENIC ACID (2121) hemihydrate needles from water m.pt 208° soluble in water		ASTHMA 104-106:301	active principle in green coffee bean may react as a phenol compound
ABIETIC ACID (1) monoclinic plates m.pt 172-175° insoluble in water		ASTHMA (immediate type) 93-100 DERMATITIS 234-236	one of the active principles in colophony pine resin used as solder, cosmetic, adhesive tapes, varnish etc commercial abietic made by heating rosin



TABLE 5c (continued) CARBOXYLIC ACIDS				
CHEMICAL	FORMULA	SYMPTOMS (WITH REFERENCES)	REMARKS	
PIMARIC ACID		ASTHMA 93-100 DERMATITIS 234-236	one of the active principles in colophony pine resin	
CARMINE ACID red prisms soluble in water		ASTHMA (dual reaction) 302 GASTRO INTESTINAL SYMPTOMS 302 ALLERGIC CHEILITIS 303 (when used as a lip salve)	Carmine- aluminium calcium lake insoluble in cold water or dilute acids. partially soluble in hot water dye (used in foods)	


TABLE 5d ACYL HALIDES				
CHEMICAL	FORMULA	SYMPTOMS (WITH REFERENCES)	REMARKS	
PHENYL GLYCINE ACID CHLORIDE		ASTHMA (immediate type) ³⁰⁴	also an irritant highly reactive - combines readily with proteins	





TABLE 5e ACID ANHYDRIDES				
CHEMICAL	FORMULA	SYMPTOMS (WITH REFERENCES)	REMARKS	
PHTHALIC ANHYDRIDE (7179) white lustrous needles m.pt 130.8° b.pt 295° sublimes soluble in water		ASTHMA (immediate and delayed reactions) ^{37; 305-309} RHINITIS ³⁰⁷	LTEL 1ppm; 6mg/m ³ STEL 4ppm; 24mg/m ³ used as hardener in epoxy resin manufacture	
TETRACHLOROPHTHALIC ANHYDRIDE		ASTHMA (immediate and late reactions) ³¹⁰	used as hardener in epoxy resin manufacture	
TRIMELLITIC ANHYDRIDE (9370) crystals m.pt 161-163°		ASTHMA (immediate and late reactions) ^{311; 312} EXTRINSIC ALLERGIC ALVEOLITIS (LRSS) ³¹² RHINITIS ³¹¹ PULMONARY DISEASE ANAEMIA SYNDROME ³¹³	used as hardener in epoxy resin manufacture and in the manufacture of plasticisers LTEL 0.04-mg/m ³	
PYROMELLITIC DIANHYDRIDE		ASTHMA (immediate type) ¹⁴⁸	used as epoxy adhesive hardener could act as cross-linking agent	

TABLE 5f AMIDES



CHEMICAL	FORMULA	SYMPTOMS (WITH REFERENCES)	REMARKS
1,2-BENZISOTHIAZOLIN-3-ONE yellow needles m.pt 137.5°		DERMATITIS ³¹⁴	used as preservative in plastic emulsions
AZODICARBONAMIDE (919) orange red crystals m.pt 225° soluble in hot water		³¹⁵ ASTHMA	used as a blowing agent in plastics manufacturing & bleach agent in cereal flour

TABLE 6a ACRYLATES

CHEMICAL	FORMULA	SYMPTOMS (WITH REFERENCES)	REMARKS
ETHYL ACRYLATE (3688) liquid f.pt -72° b.pt 99.4° polymerises on distillation	$\text{CH}_2=\text{CH}-\overset{\text{O}}{\parallel}\text{C}-\text{OC}_2\text{H}_5$	DERMATITIS ³¹⁶	LTEL 25ppm; 100mg/m ³
BUTYL ACRYLATE (1523) liquid b.pt 148° soluble in water	$\text{CH}_2=\text{CH}-\overset{\text{O}}{\parallel}\text{C}-\text{O}-\underset{\text{CH}_3}{\underset{\text{CH}_3}{\text{C}}}-\text{CH}_2-\overset{\text{O}}{\parallel}\text{C}-\text{CH}=\text{CH}_2$	DERMATITIS ³¹⁶	LTEL 10ppm; 55mg/m ³
GLYCIDYL ACRYLATE	$\text{CH}_2=\text{CH}-\overset{\text{O}}{\parallel}\text{C}-\text{O}-\text{CH}_2-\text{CH}-\text{CH}_2$	DERMATITIS ³¹⁸	
AMMONIUM ACRYLATE	$\text{CH}_2=\text{CH}-\overset{\text{O}}{\parallel}\text{C}-\text{O}^-\text{NH}_4^+$	ASTHMA ¹⁷² DERMATITIS ¹⁷²	
2-ETHYL BUTYL ACRYLATE b.pt 82°	$\text{CH}_2=\text{CH}-\overset{\text{O}}{\parallel}\text{C}-\text{O}-\underset{\text{H}}{\underset{\text{C}_2\text{H}_5}{\text{CH}}}-\text{CH}_2-\text{CH}_2-\overset{\text{O}}{\parallel}\text{C}-\text{CH}=\text{CH}_2$	DERMATITIS ²¹⁹	
2-ETHYL HEXYL ACRYLATE b.pt 130° insoluble in water	$\text{CH}_2=\text{CH}-\overset{\text{O}}{\parallel}\text{C}-\text{O}-\underset{\text{H}}{\underset{\text{C}_2\text{H}_5}{\text{CH}}}-\text{CH}_2-\text{CH}_2-\text{CH}_2-\text{CH}_2-\overset{\text{O}}{\parallel}\text{C}-\text{CH}=\text{CH}_2$	DERMATITIS ²¹⁹	
1,6 HEXANE DIOL DIACRYLATE	$\text{CH}_2=\text{CH}-\overset{\text{O}}{\parallel}\text{C}-\text{O}-\underset{\text{CH}_2}{\underset{\text{CH}_2}{\text{C}}}-\text{O}-\overset{\text{O}}{\parallel}\text{C}-\text{CH}=\text{CH}_2$	DERMATITIS ^{209 : 213 : 214}	

TABLE 6a (continued) ACRYLATES					
CHEMICAL	FORMULA	SYMPTOMS (WITH REFERENCES)	REMARKS		
TRIMETHYLOL PROPANE TRIACRYLATE (TMPTA)	$ \begin{array}{c} \text{CH}_3 \\ \\ \text{CH}_2 \\ \\ \text{CH}_2 = \text{CH} - \text{CO} - \text{CH}_2 - \text{C} - \text{CH}_2 - \text{OC} - \text{CH} = \text{CH}_2 \\ \\ \text{CH}_2 - \text{OC} - \text{CH} = \text{CH}_2 \end{array} $	DERMATITIS 209-211; 213; 214; 308	used in manufacture of UV cured inks animal studies 317		
PENTA ERYTHRITOL TRIACRYLATE (PETA)	$ \begin{array}{c} \text{CH}_2\text{OH} \\ \\ \text{CH}_2 = \text{CH} - \text{CO} - \text{CH}_2 - \text{C} - \text{CH}_2 - \text{OC} - \text{CH} = \text{CH}_2 \\ \\ \text{CHO} - \text{CH} = \text{CH}_2 \end{array} $	DERMATITIS 209-211; 213; 214; 308	used in manufacture of UV cured inks		
DIPENTA ERYTHRITOL MONOHYDROXY PENTA ACRYLATE (DEMPA)	$ \begin{array}{c} \text{CH}_2\text{OH} \\ \\ \text{CH}_2 = \text{CH} - \text{CO} - \text{CH}_2 - \text{C} - \text{CH}_2 - \text{OC} - \text{CH} = \text{CH}_2 \\ \\ \text{CHO} - \text{CH} = \text{CH}_2 \end{array} $	DERMATITIS 210; 308	used in manufacture of UV cured inks		
TRIPROPYLENE GLYCOL TRIACRYLATE	$ \begin{array}{c} \text{OC} - \text{CH} = \text{CH}_2 \\ \\ \text{CH}_2 = \text{CH} - \text{CO} - \text{C} - \text{CH} = \text{CH}_2 \\ \\ \text{OC} - \text{CH} = \text{CH}_2 \end{array} $	DERMATITIS 211	used in the manufacture of UV cured inks		

TABLE 6b METHACRYLATES

CHEMICAL	FORMULA	SYMPTOMS (WITH REFERENCES)	REMARKS
METHYL METHACRYLATE b.pt 101° slightly soluble in water	$\text{CH}_2=\underset{\text{CH}_3}{\underset{ }{\text{C}}}-\overset{\text{O}}{\underset{ }{\text{C}}}-\text{OCH}_3$	ASTHMA ¹⁷³ DERMATITIS ²²¹ ; ³²⁰	LTEL 100ppm; 410mg/m ³ STEL 125ppm; 510mg/m ³ animal studies ³²¹
ETHYL METHACRYLATE b.pt 117° slightly soluble in water	$\text{CH}_2=\underset{\text{CH}_3}{\underset{ }{\text{C}}}-\overset{\text{O}}{\underset{ }{\text{C}}}-\text{OC}_2\text{H}_5$	DERMATITIS	animal studies ³²¹
N-BUTYL METHACRYLATE b.pt 160° insoluble in water	$\text{CH}_2=\underset{\text{CH}_3}{\underset{ }{\text{C}}}-\overset{\text{O}}{\underset{ }{\text{C}}}-\text{OC}_4\text{H}_9$	DERMATITIS	animal studies ³²¹
2-HYDROXYETHYL METHACRYLATE	$\text{CH}_2=\underset{\text{CH}_3}{\underset{ }{\text{C}}}-\overset{\text{O}}{\underset{ }{\text{C}}}-\text{OC}_2\text{H}_4\text{OH}$	DERMATITIS ³²² ; ³²³	
DIETHYLENEGLYCOL DIMETHACRYLATE	$\text{CH}_2=\underset{\text{CH}_3}{\underset{ }{\text{C}}}-\overset{\text{O}}{\underset{ }{\text{C}}}-\text{O}(\text{CH}_2\text{CH}_2\text{O})_2\overset{\text{O}}{\underset{ }{\text{C}}}-\underset{\text{CH}_3}{\underset{ }{\text{C}}}=\text{CH}_2$	DERMATITIS ³²² ; ³²³	
TETRAETHYLENEGLYCOL DIMETHACRYLATE	$\text{CH}_2=\underset{\text{CH}_3}{\underset{ }{\text{C}}}-\overset{\text{O}}{\underset{ }{\text{C}}}-\text{O}(\text{CH}_2\text{CH}_2\text{O})_4\overset{\text{O}}{\underset{ }{\text{C}}}-\underset{\text{CH}_3}{\underset{ }{\text{C}}}=\text{CH}_2$	DERMATITIS ³²² - ³²⁴	
1-HYDROXYPROPYL METHACRYLATE	$\text{CH}_2=\underset{\text{CH}_3}{\underset{ }{\text{C}}}-\overset{\text{O}}{\underset{ }{\text{C}}}-\text{OC}_3\text{H}_7\text{OH}$	DERMATITIS ²¹⁹	

TABLE 6c ACRYLAMIDES				
CHEMICAL	FORMULA	SYMPTOMS (WITH REFERENCES)	REMARKS	
ACRYLONITRILACRYLAMIDE	$\text{CH}_2=\text{CH}-\overset{\text{O}}{\parallel}\text{C}-\text{N}=\text{N}-\text{CH}=\text{CH}_2$	DERMATITIS ³¹⁹		
N,N' METHYLENE BIS ACRYLAMIDE	$\text{CH}_2=\text{CH}-\overset{\text{O}}{\parallel}\text{C}-\text{NCN}-\overset{\text{O}}{\parallel}\text{C}-\text{CH}=\text{CH}_2$	DERMATITIS ³²⁵	used in printing	
ACRYLAMIDE (125) crystals m.pt 84.5° soluble, polymerises	$\text{CH}_2=\text{CH}-\overset{\text{O}}{\parallel}\text{C}-\text{NH}_2$	DERMATITIS ^{322, 325}	LT _{EL} 0.3 mg/m ³ ST _{EL} 0.6 mg/m ³	
METHACRYLAMIDE	$\text{CH}_2=\overset{\text{CH}_3}{\underset{\text{O}}{\parallel}}\text{C}-\text{NH}_2$	DERMATITIS ³¹⁹		
DIACETONE ACRYLAMIDE (2920) m.pt 57° white crystalline solid	$\text{CH}_2=\text{CH}-\overset{\text{O}}{\parallel}\text{C}-\text{N}-\overset{\text{CH}_3}{\underset{\text{H}}{\text{C}}}-\overset{\text{CH}_3}{\underset{\text{O}}{\parallel}}\text{C}-\text{CH}_3$	DERMATITIS ³¹⁹		
N-METHYLOL ACRYLAMIDE	$\text{CH}_2=\text{CH}-\overset{\text{O}}{\parallel}\text{C}-\text{NCH}_2\text{OH}$	DERMATITIS ^{322, 325, 326}		

TABLE 6d ISOCYANATES





CHEMICAL	FORMULA	SYMPTOMS (WITH REFERENCES)	REMARKS
TOLUENE DIISOCYANATE (TDI) (9226) liquid m.pt 19.5-20.5° b.pt 251° polymerises reacts with water to give CO ₂		154:157; 159-161; 164; 170; 197; ASTHMA (immediate, late and dual reactions) 199-201 EXTRINSIC ALLERGIC ALVEOLITIS 165; 169	LTEL 0.02 mg/m ³ [CL] STEL 0.07 mg/m ³ [CL] used in manufacture of flexible and rigid foams, synthetic rubbers and paint
DIPHENYL METHANE DIISOCYANATE (MDI)		155; 162-164; 168; 170; 195; 205 ASTHMA EXTRINSIC ALLERGIC ALVEOLITIS 165; 168; 204; 205 DERMATITIS 193; 195	LTEL [CL] 0.02 mg/m ³ STEL [CL] 0.07 mg/m ³
1,5-NAPHTHYLENE DIISOCYANATE		ASTHMA 167	
ISOPHORONEDIISOCYANATE (IPDI)		166; 203 ASTHMA	LTEL [CL] 0.02 mg/m ³ STEL [CL] 0.07 mg/m ³

TABLE 6d (continued) ISOCYANATES				
CHEMICAL	FORMULA	SYMPTOMS (WITH REFERENCES)	REMARKS	
HEXAMETHYLENE DIISOCYANATE	OCNCH ₂ CH ₂ CH ₂ CH ₂ CH ₂ CH ₂ NCO	ASTHMA 166:170	LTEL 0.02 mg/m ³ [CL] STEL 0.07 mg/m ³ [CL]	





CHEMICAL	FORMULA	SYMPTOMS (WITH REFERENCES)	REMARKS
SUDAN I	 <chem>Oc1ccc2ccccc2c1=N=Nc3ccccc3</chem>	DERMATITIS ³³¹	
SUDAN II	 <chem>Cc1cc(C)ccc1=N=Nc2cc(O)ccc3ccccc23</chem>	DERMATITIS ³³¹	
SUDAN III	 <chem>Oc1ccc2ccccc2c1=N=Nc3ccccc3=N=Nc4ccccc4</chem>	DERMATITIS ³³¹	
VACANCEINE RED	 <chem>Oc1ccc2ccccc2c1=N=Nc3ccccc3c4ccccc4</chem>	DERMATITIS ³³¹	

TABLE 6e (continued) REACTIVE DYES





CHEMICAL	FORMULA	SYMPTOMS (WITH REFERENCES)	REMARKS
ORANGE SS		PIGMENTED CONTACT DERMATITIS ³³¹	
YELLOW OB		PIGMENTED CONTACT DERMATITIS ³³¹	
BRILLIANT LAKE RED R		PIGMENTED CONTACT DERMATITIS ^{331;332}	
DIAZOBENZENE SULPHONIC ACID		EXTRINSIC ALLERGIC ALVEOLITIS ³³⁴ ^{176; 335} ASTHMA	







TABLE 7a EPOXIDES				
CHEMICAL	FORMULA	SYMPTOMS (WITH REFERENCES)	REMARKS	
EPICHLORHYDRIN (3536) liquid m.pt-25.6° b.pt 117.9° insoluble		²⁸⁷ listed as strong respiratory sensitiser but sensitisation not confirmed	LTEL 2ppm; 8mg/m ³ STEL 5ppm; 20mg/m ³	
EPOXIDE 7		DERMATITIS ³³⁶		
ALLYL GLYCIDYL ETHER		DERMATITIS ²⁸⁷	LTEL 5ppm; 22mg/m ³ STEL 10ppm; 44mg/m ³	
n BUTYL GLYCIDYL ETHER		DERMATITIS ²⁸⁷	LTEL 50 ppm; 270mg/m ³	
DIGLYCIDYL ETHER		DERMATITIS ²⁸⁷	LTEL & STEL 0.5ppm; 3mg/m ³	
PHENYL GLYCIDYL ETHER		DERMATITIS ²⁸⁷		
SEE ALSO :- GLYCIDYL ALDEHYDE GLYCIDYL ACRYLATE	TABLE 5a PAGE 49 TABLE 6a PAGE 59			

TABLE 7b IMINES				
CHEMICAL	FORMULA	SYMPTOMS (WITH REFERENCES)	REMARKS	
ETHYLENE IMINE (3748) liquid, polymerises easily. b.pt 56-57. miscible with water	$ \begin{array}{c} \text{H} \\ \diagup \quad \diagdown \\ \text{N} \\ \diagdown \quad \diagup \\ \text{HC} \quad \text{CH}_2 \end{array} $	DERMATITIS ^{287;337}	LT _{EL} 0.5ppm; 1mg/m ³ widely used in many industries including polymer manufacturing	

TABLE 8 AMINES				
CHEMICAL	FORMULA	SYMPTOMS (WITH REFERENCES)	REMARKS	
ETHYLENE DIAMINE (3731) liquid b.pt 116° m.pt 8.5° soluble volatile with steam	$\text{H}_2\text{NCH}_2\text{CH}_2\text{NH}_2$	ASTHMA (late reaction) ^{338; 339; 341} DERMATITIS ³⁴²⁻³⁴⁷	LTEL 10ppm; 25mg/m ³ irritant vapour used as solvent for shellac in developing photographs in preparation of dyes etc.	
HYDRAZINE (4653) liquid b.pt 120.3° solvent, miscible with water	H_2NNH_2	DERMATITIS ³⁴⁸	LTEL 0.1ppm; 0.1mg/m ³	
DIETHYL TETRAMINE		DERMATITIS ³⁴¹		
DIETHYLENE TRIAMINE	$\text{H}_2\text{NCH}_2\text{CH}_2\text{NH}$ $\text{H}_2\text{NCH}_2\text{CH}_2$	ASTHMA ³⁵⁰ DERMATITIS	LTEL 1ppm; 4mg/m ³	
TRIETHYLENE TETRAMINE	$\text{H}_2\text{NCH}_2\text{CH}_2\text{NCH}_2\text{CH}_2\text{NCH}_2\text{CH}_2\text{NH}_2$	ASTHMA ^{37; 351} DERMATITIS ^{151; 341}		
ETHANOLAMINE (3654) viscous hygroscopic liquid b.pt 170.8° strong base miscible	$\text{HOCH}_2\text{CH}_2\text{NH}_2$	ASTHMA ³³⁹	LTEL 3ppm; 8mg/m ³ STEL 6ppm; 15mg/m ³ no obvious cause for allergic reaction	
DIMETHYL ETHANOLAMINE	$\text{HOCH}_2\text{CH}_2\text{N}(\text{CH}_3)_2$	ASTHMA (dual response) ³⁶⁰ RHINITIS ³⁶⁰	no obvious cause for allergic reaction may be impurities	




TABLE 8 (continued) AMINES				
CHEMICAL	FORMULA	SYMPTOMS (WITH REFERENCES)	REMARKS	
AMINOETHYL ETHANOLAMINE	$\text{HOCH}_2\text{CH}_2\text{N}(\text{H})\text{CH}_2\text{CH}_2\text{NH}_2$	ASTHMA ^{361; 362}	no obvious cause for allergic reaction may be impurities	
CHLORAMINE T (2038) trihydrate prism fairly soluble in water	$\text{CH}_3\text{C}_6\text{H}_4\text{SO}_2\text{NNaCl}$	ASTHMA (immediate and late reactions) ^{363; 364} DERMATITIS ^{363; 365; 366}	oxidising agent - can oxidise proteins	
PIPERAZINE (7254) leaflets from alcohol m.pt 106° b.pt 146° strong base, absorbs CO ₂ & H ₂ O from air		ASTHMA (late reaction) ^{352 - 354} DERMATITIS (immediate type wheal) ^{355 - 357}		
HEXAHYDRO 1,3,5- TRIACRYLOYL S TRIAZINE		DERMATITIS ³¹⁸	may cross link protein	
PYRAZOLINE (7745) liquid b.pt 144° volatile with steam miscible with water		DERMATITIS (pigmented) ³⁵⁹	metabolites may be important	

TABLE 8 (continued) AMINES





CHEMICAL	FORMULA	SYMPTOMS (WITH REFERENCES)	REMARKS
p-PHENYLENE DIAMINE (1,4 diaminobenzene) (7089) white/red crystal m.pt 145-147° b.pt 267° soluble in water		ASTHMA ^{252; 287; 339} DERMATITIS ³⁴⁴	LTEL 0.1mg/m ³ solvent in paint making accelerator in rubber production, used in fur industry may oxidise to quinone
ISOPROPYL PHENYL PARAPHENYLENE DIAMINE (IPPD)		DERMATITIS ^{227 - 233}	used in rubber manufacture
N,N'-DIPHENYL-p-PHENYL ENE DIAMINE (DPPD) (3342) colourless leaflets m.pt 150 insoluble in water		DERMATITIS ²²⁸	used in rubber manufacture
N-PHENYL-N'-CYCLO HEXYL-p-PHENYLENE DIAMINE (CPPD)		DERMATITIS ²²⁸	used in rubber manufacture

TABLE 9 THIOLS				
CHEMICAL	FORMULA	SYMPTOMS (WITH REFERENCES)	REMARKS	
PENTAERYTHRITOL TETRAKIS 3- MERCAPTOPROPIONATE	$\begin{array}{c} \text{O} \\ \parallel \\ \text{CH}_2\text{OCCH}_2\text{CH}_2\text{SH} \\ \\ \text{HSCH}_2\text{CH}_2\text{COCH}_2\text{CCH}_2\text{OCCH}_2\text{CH}_2\text{SH} \\ \parallel \qquad \qquad \qquad \parallel \qquad \qquad \qquad \parallel \\ \text{O} \qquad \qquad \qquad \text{O} \qquad \qquad \qquad \text{O} \\ \\ \text{CH}_2\text{OCCH}_2\text{CH}_2\text{SH} \end{array}$	DERMATITIS ^{223:225} RHINITIS ²²³	asthma also reported but not clearly established as allergic	

been included. Reports of allergic contact dermatitis to related chemicals have been included for comparison purposes.

4.2 Bonding to protein

Strength or stability of bonds between a carrier molecule and a small hapten plays a critical role in the determination of its biological properties. Since haptens have to form stable complexes with carrier proteins in order to react with the immune system it has long been accepted that covalent binding of these units is ^{368,369}necessary. Weaker bonds (ionic or dipole including hydrogen bonding) can serve only when multiple bonds provide the necessary cumulative energy to the complex.

Carbonyl, amino and similar groups on haptenic molecules are therefore prime candidates for this task. Reactive anhydrides, quinones and acid chlorides have been shown to form hapten-protein conjugates by linking of their constituent carbonyl groups with amino groups of amino acid residues of protein. Similarly the isocyanate group of the various reactive aliphatic and aromatic isocyanates known to induce allergic reactions, is thought to be responsible for covalent attachment to protein. TDI is ³⁸capable of combining with -NH_2 , -OH , -SH and -COOH ³⁷⁰groups as well as undergoing self polymerisation and still retaining reactive isocyanate ³⁷¹groups. In the case of ¹⁰reactive dyes covalent bonding between heterocyclic

halogen groups on the molecule and amino or hydroxyl functions of protein side chains can occur.¹⁰ Indeed this type of linkage is used in the dyeing process.

The reactive side chains of amino acid residues commonly present in proteins and likely to be involved in protein binding to haptens are shown in table 10. The structures of probable haptens formed by several classes of reactive organic compounds with protein (linked via side chain groupings) are shown in figure 7.

The presence of unsaturated bonds in haptenic molecules does not seem to influence protein binding. In the case of abietic acid and pimaric acid (found in colophony resin) the unsaturated double bonds of these acids seem to be less important for protein binding than the carbonyl groups.⁹⁵ Similar evidence¹⁵⁶ has also been found in the case of TDI.

4.3 Conjugates

Molecules with more than one functional group capable of binding to protein may give rise to several different conjugates. Even with a given protein a molecule with two or more of the same functional groups may form two or more conjugates of separate structure. The position is further complicated in the case of molecules having different functional groups. With plicatic acid (found in Western Red Cedar) for example, carbonyl groups on the molecule could bind with lysine or arginine residues on a given protein to form a complex whilst alternatively

TABLE 10.

REACTIVE AMINO ACID SIDE CHAINS OF PROTEINS AVAILABLE
FOR BINDING TO REACTIVE ORGANIC MOLECULES






SERINE	$\text{HO}-\text{CH}_2-$
THREONINE	$\text{CH}_3-\underset{\text{OH}}{\underset{ }{\text{CH}}}-$
TYROSINE	
HYDROXYPROLINE	
ASPARTIC ACID	$\text{HOOC}-\text{CH}_2-$
GLUTAMIC ACID	$\text{HOOC}-\text{CH}_2-\text{CH}_2-$
ARGININE	$\text{NH}_2-\underset{\text{H}}{\underset{ }{\text{C}}}-\underset{\text{H}}{\text{N}}-\text{CH}_2-\text{CH}_2-\text{CH}_2-$
LYSINE	$\text{NH}_2-\text{CH}_2-\text{CH}_2-\text{CH}_2-\text{CH}_2-$
HISTIDINE	
TRYPTOPHAN	


FIGURE 7.

STRUCTURES OF PROBABLE HAPTENS RESULTING FROM THE REACTIONS
OF SIMPLE ORGANIC CHEMICALS WITH PROTEIN. ([P])


ALDEHYDES




QUINONES



CARBOXYLIC ACIDS



ACYL HALIDES



ACID ANHYDRIDES






FIGURE 7. (continued)

STRUCTURES OF PROBABLE HAPTENS


EPOXIDES



ISOCYANATES



REACTIVE DYES



other functional groups present may be capable of binding with separate amino acid residues on different proteins to form other complexes. Studies on plicatic³⁷² acid using a human serum albumin conjugate (linked to the carboxyl group of the acid by an amide bond) seem to indicate however that the protein in vivo is connected not by this linkage but through one of the groups in the catechol ring (possibly an hydroxyl group.)

The availability of a particular protein at or near the site of invasion into the body by the reactive chemical will clearly determine which conjugate or conjugates are formed. Since a particular agent entering via the lungs is likely to encounter some different proteins to those found when entering via the skin a totally different conjugate is likely to be produced at each site which in turn may lead to different types of reaction being elicited at each of the sites concerned.

Any given carrier protein molecule is likely to have several side groups capable of combining with molecules of the invading haptenic chemical and accordingly the conjugate formed is likely to consist of many haptenic residues joined to a single protein. The total number of residues joined would be expected to be influenced by the relative local concentrations of hapten and carrier protein, the number of available reactive groups of the appropriate type on the protein and their accessibility to the hapten molecules.


³⁷³
In one study involving a TDI-HSA protein conjugate the molecular ratio of the complex was found to be 34 molecules of isocyanate per molecule of protein. However, in a similar ³⁷⁴ study also using TDI-HSA conjugates it was found that conjugates with 18 to 20 molecules of isocyanate per molecule of protein were more potent antigens than those with greater isocyanate content.

The significance of this is not clear. It is possible that with a large number of haptenic residues on a protein some cross-linking may occur thereby effectively changing the structure of the conjugate and therefore the functional groups capable of acting as an antigenic determinant. Alternatively, a large number of haptenic residues together may reduce the antigenic potential purely through steric hindrance of certain key groups.

Investigations of the mechanism of isocyanate hypersensitivity have been undertaken by several groups of workers involving ^{357:382-386} animal studies using mice or guinea pigs. Various hapten-protein conjugates have been employed as test antigens to stimulate allergic reactions and to investigate the specificity of antibody produced by isocyanate sensitised workers or test animals. Mono isocyanate compounds have generally been used for antigen formation in preference to diisocyanates to avoid cross-linking of proteins in conjugate formation.

The results generally indicate that the isocyanate group is involved in protein binding via an ureido linkage probably with lysine side chains. Other parts of the isocyanate molecule are involved as part of the antigenic determinant. Additional isocyanate groups (as in the diisocyanate molecule) probably in vivo engage in crosslinking proteins and therefore form complex antigenic determinants.

³⁸⁷
Studies of acrylates and methacrylates in the guinea pig suggest that the presence of an alpha carbon group in the latter molecule decreases its sensitising potential when compared to its acrylate analogue. This may be due in part to steric hindrance affecting the reaction of active groups on the molecule with protein. The linkage to carrier protein would be expected to be formed by displacement of the alkyl group at the alkoxy linkage.



This steric hindrance effect could be acting by decreasing the protein binding potential and so reducing the creation of a potential allergen conjugate in the first place.

The methyl group could also be affecting the reactivity of the molecule generally and its susceptibility to attack by protein side chain groups.

Similar evidence has been found from other studies. Comparison of the reactivity of a series of alpha alkyl substituted cinnamaldehydes towards primary amines showed³⁸⁸ that the substituted aldehydes reacted very slowly compared to cinnamaldehyde itself. Since the reaction between aldehyde and amine corresponds to that between aldehyde and the $-NH_2$ group of protein this evidence suggests that the substituted aldehydes will not react readily with proteins and that conjugate formation is unlikely. Indeed the substituted aldehydes are found not to be sensitisers. In this case the substituent is thought to reduce the chemical reactivity of the aldehyde group.

Patients sensitised to acrylates in adhesive tape were found²¹⁹ to exhibit a broad cross-reaction pattern with acrylic esters yet failed to respond to methyl methacrylate. In particular they reacted readily to 2-ethyl hexyl acrylate but did not respond to the methacrylate analogue. The methacrylate compounds may have only reacted weakly with protein (if at all) and not formed a strong complex which the 'acrylate receptors' in the sensitised patients could recognise.

4.4 Active Sites


Obviously the site of the chemical linkage between the invading chemical and the carrier protein influences which other parts of the molecule function as the relative

antigenic determinant for the induction of, and subsequent reaction with, specific IgE antibodies in sensitised workers. In the case of very small molecules, the whole of the invading chemical moiety (including groups linking it to protein) as well as part of the protein itself are likely to constitute the antigenic determinant.

With larger and more complex molecules this may not be the case and indeed only part of the chemical may be involved in the active site. Evidence from animal studies on acrylates³²¹ for example, suggests that the alcohol part of the ester molecule is not involved in influencing the sensitising potential of mono acrylates.

However, since binding of the hapten with carrier protein is an essential prerequisite of the observed allergic response it is probable that groups on the protein constitute an essential part of the active site. Indeed, several studies have shown that the specificity of antibody produced in response to protein conjugates is directed not only against the chemical groupings attached to the protein but also some of the amino acid residues of the carrier protein.

Studies on workers hypersensitive to phenyl glycine acid³⁰⁴ chloride indicated that the specific antibody produced to the complex formed recognised part of the protein molecule extending beyond the hapten and the lysine residue of the protein molecule through which it was joined.



Similarly in the case of allergy to trimellitic anhydride
³⁸⁹
 it has been demonstrated that the antigenic determinant
 involves at least one amino acid of the carrier protein
 as well as groups on the hapten part of the conjugate.

³⁷⁶
 In studies on respiratory hypersensitivity in the guinea
 pig the animals were exposed to an aerosol antigen using
 p-arsanilic acid and p-tolyl diisocyanate as haptens
 coupled with ovalbumin or bovine serum albumin. The hapten-
 specific nature of the pulmonary reactions was demonstrated
 by a) a response to challenge with hapten-protein conjugates
 and the lack of response to challenge with protein carrier
 alone, and b) by reactivity upon challenge with hapten
 coupled to unrelated heterologous carriers.

The active site and the antigenic determinant formed (which ultimately triggers the allergic response) by one hapten conjugated with a given protein may be similar to that formed by a different hapten conjugated with an alternative protein. The essential point being that the position and pattern of accessible functional groups present on the conjugate and so available to react with antibody need to be the same or very similar.

Indeed, cross reactivity between isophore diamine and isophore diisocyanate has been observed: ³⁹⁰ this would tend to suggest that the part of the molecule reacting with antibody does not contain an isocyanate group, and if the isocyanate group is employed in binding to carrier protein and the amine groups of the diamine undertake a similar role then different protein-hapten links will be formed. However, the active site produced in the two cases could still be similar and may account for the observed results.

The functional groups present at an active site (whether from the hapten or carrier protein parts of the complex) must stimulate a reaction with receptors present on the appropriate circulating memory cells in order for antibody to be produced and an allergic reaction to be triggered. These groups, like those involved in binding to the carrier, will need to be polar thereby enabling them to induce reactions with amino, hydroxyl and similar groups at the receptor site.

Unsaturated carbon chains also appear to be involved as part of the active site in some haptens (eg. acrylates and isocyanates) and not for conjugate formation. Non-reactive saturated carbon chains are unlikely to stimulate reaction with receptors.

The majority of haptens detailed in tables 5 to 9 have more than one functional group thereby providing for at least one group to be involved in binding to carrier protein and one or more groups for acting as the active site.

The groups involved in the conjugate formation could still be part of the active site but their influence would be much reduced. However, in the case of formaldehyde, for example, with only one functional group it must be involved in both activities and may induce an antigenic determinant merely by altering the local configuration of the carrier protein.

Diamines may react by cross-linking proteins or parts of proteins to form key groupings which constitute the antigenic determinant.

As indicated above whether one haptenic residue on a carrier protein constitutes one antigenic determinant or whether several haptenic residues on the one protein in close spatial proximity are needed is not clear. With smaller molecules the latter case is more likely since the slight change in protein configuration brought about by joining of an odd group or two is likely to be of marginal significance.

Cross reactivity between related chemicals provides some information about functional groups implicated as antigenic determinants or as part of the active site. In cases of allergic contact dermatitis, patients sensitised to one particular chemical often give positive skin reactions to related compounds. However, it is difficult to conclude that the observed response to the related chemicals is indeed mounted by the same antibodies as those to the original sensitiser or whether the patient is actually sensitised to each of the chemicals being tested. This latter situation may well prevail in susceptible individuals where a particular working environment exposes them not only to the principal chemical but also traces of related chemicals (possibly present as impurities) to which they also become sensitised.

ACID ANHYDRIDES

5.1 Introduction

Anhydrides are widely used in industry. In particular they are one of the principal types of curing agent (hardener) used in the manufacture of epoxy resin plastics. Epoxy resin, made by polymerising a phenol and epichlorhydrin, will polymerise spontaneously at high temperature but the process is expedited by hardeners or curing agents. Curing of the resin is brought about by chemical splitting of the epoxide ring leading to cross linkage between the long chain resin molecules producing three-dimensional structures. External heat is often necessary but the reaction is generally exothermic and during the curing process fumes of resin and curing agent are emitted. (Amines and polyamides are also used as curing agents.)

Phthalic anhydride is used in a wide variety of industrial processes; ³⁹¹ 60% as plasticiser in vinyl chloride polymerisation; 30% for polyester resin manufacture and in pesticides, essences and perfumes; 10% in the production of alkyd resins in paints and lacquers and in the preparation of benzoic acid. Trimellitic anhydride is also used as a raw material in the manufacture of plasticisers and in the production of resins with hydroquinone and aromatic diamines.

Dermatitis to epoxy resin systems and their components (including anhydride curing agents) is well known. ³⁹² The presentation of dermatitis may be either acute or chronic.

Acute cases show marked oedema of the face and eyelids or of the hands and genitalia, sometimes with large blisters or exudation of serum - suggesting a contact dermatitis from allergy to vapourised resin. Subacute or chronic cases more usually affect the hands and fingers as areas of red, scaly papulovesicular dermatitis but sometimes show lichenification fissuring or psoriasiform appearance - often difficult to diagnose without patch tests and may be due to direct contact with the resin or hardener.

5.2 Respiratory sensitisation

Cases of respiratory sensitisation to four common anhydrides (phthalic anhydride, tetrachlorophthalic anhydride, trimellitic anhydride and pyromellitic dianhydride) have been reported. Formulae and a summary of the observed symptoms are given in table 5e. Case histories of 3 workers apparently sensitised to anhydrides are summarised in figures 8,9 & 10.

Phthalic anhydride is a recognised irritant to the respiratory tract and asthma often develops. Several cases of asthma due to hypersensitivity to the powder and/or its fumes are known - the earliest report being by Kern in 1939. Recently³⁰⁵ phthalic anhydride has been implicated as one of the causal agents responsible for 'meat wrapper's asthma'.³⁹³

Tetrachlorophthalic anhydride is also known³¹⁰ to cause sensitisation giving rise to a clinical and physiological response indicative of a combined immunologic reaction.

FIGURE 8.CASE HISTORY OF PATIENT WITH APPARENT RESPIRATORY ALLERGY TO
AN EPOXY ADHESIVE CONTAINING PYROMELLITIC DIANHYDRIDE AS HARDENER¹⁴⁸

The patient had worked with an epoxy resin cured with pyromellitic dianhydride powder, including the mixing of the chemicals and curing of the mixture at 180°C. She had no previous history of hay fever or asthma prior to using the adhesive and did not experience dyspnea on exertion or chronic bronchitis. Whilst she experienced nasal symptoms and wheeze using the adhesive they were much more severe when she mixed it.

Respiratory function tests were undertaken at the workplace. The first reading and one taken 30 minutes later were used as a baseline and subsequent readings expressed as a percentage of it. FEV₁ and FVC were repeated at intervals of 10, 20, 30, 60 and 120 minutes after exposure to the mixed adhesive. The subject declined to be tested when mixing the adhesive. The results are tabulated below.


The subject was also tested after inhaling cromoglycate at 20.30 hours the previous evening and 06.00 hours on the morning of the test. The results (as shown on the graph below) indicate little benefit from its use.

FIGURE 8 (continued).CASE HISTORY OF PATIENT WITH APPARENT RESPIRATORY ALLERGY TOAN EPOXY ADHESIVE CONTAINING PYROMELLITIS DIANHYDRIDE AS HARDENER

USING MIXED ADHESIVE

Nasal symptoms	+
Respiratory symptoms	+
Time of wheeze (minutes)	45
Fall in FEV_1 (%)	15
Time of fall (minutes)	10
DURATION OF EXPOSURE (MONTHS)	12
ORIGINAL FEV_1 (LITRES)	1.97

The subject was not atopic, did not smoke and gave negative results on prick testing.



Change in FEV_1 as a percentage of base-line values

FIGURE 9.CASE HISTORY OF PATIENT WITH ASTHMA DUE TO SENSITISATION TO
³⁷
PHTHALIC ANHYDRIDE

The patient worked as a tool setter in a plastics factory specialising in plastics moulding. He had been free of illness until 10 years previous, since when he had minor episodes of acute bronchitis without wheezing, attributed to upper respiratory tract infection. He had smoked 20 cigarettes per day all his working life.

He was responsible for setting up a new machine for encapsulating electrical coils in epoxy resin. The process used a moulding powder of blended epoxy resin with phthalic acid anhydride as curing agent. The powder was fed from a hopper into the mould of the machine around the coil, where it was heated to 150°C. The worker was exposed to large amounts of the fume produced.

He collapsed with severe asthma whilst operating the machine some five months later (although he had no chest symptoms in the meantime) and was admitted to hospital. Asthma recurred when he started work again and followed immediately after exposure to the moulding powder fumes. He was subsequently transferred to a different job.

He was referred for inhalation challenge testing sometime later, and at the time of the investigation had not been exposed to the fumes for 3 months but still experienced occasional wheezing.

FIGURE 9 (continued).

CASE HISTORY OF PATIENT WITH ASTHMA DUE TO SENSITISATION TO
PTHALIC ANHYDRIDE

The results of pulmonary function tests are tabulated below,
 and the results of the inhalation challenge expressed graphically.

	Actual	% Predicted
FEV ₁ (ml)	2880	79
FVC (ml)	5180	104
FEV ₁ /FVC (%)	55.6	
VC (ml)	4950	99
FRC (ml)	5490	129
TLC (ml)	9190	123

Immediate asthmatic reaction to one breath of fume from phthalic acid anhydride-epoxy resin (●--●) Control with epoxy resin only (●—●) No reaction to a toluene diisocyanate system (●....●)




FIGURE 10.CASE HISTORY OF PATIENT WITH APPARENT RESPIRATORY ALLERGY
TO TRIMELLITIC ANHYDRIDE (TMA)³¹¹


The patient had worked for several years in the bagging area of a TMA plant. After a few months of exposure he developed nasal pruritis, rhinorrhea and conjunctivitis to the TMA dust. After a period of years he began to have respiratory symptoms on the job consistent with asthma. He used an isoproterenol inhaler to help him through the work shift. As the symptoms progressed he noted wheezing which persisted throughout the night with cough dyspnea and associated arthralgia, myalgia, chills and fever and was subsequently removed from work.

Six months later pulmonary function studies were undertaken both before and after a ten minute exposure in the workplace environment. (TMA dust concentration in this area was 3.3 mg/m^3) His response to this is shown in the graph below. He developed rhinitis and conjunctivitis 5 minutes after onset of exposure and complained of chest tightness and dyspnea shortly thereafter. Physical examination revealed conjunctival erythema, rhinorrhea and marked expiratory wheezes throughout both lung fields which had not been present on physical examination before entering the warehouse. This exposure was not followed by the return of asthma later in the day.

Immunological studies were subsequently undertaken using Trimellitic anhydride human serum albumin conjugate (TMA-HSA) He reacted to this conjugate on skin testing and had 936 mg/ml total IgE . Specific IgE and IgG levels were determined by

FIGURE 10 (continued)CASE HISTORY OF PATIENT WITH APPARENT RESPIRATORY ALLERGY
TO TRIMELLITIC ANHYDRIDE (TMA)

polystyrene tube radioimmunoassay and found to be 11200 cpm and 10805 cpm respectively above control levels.



Changes in FVC (o-o) and FEV₁ (●-●)


Serum from the patient was able to transfer immediate hypersensitivity to the skin of the rhesus monkey.

Peripheral blood leucocyte histamine release was determined by incubating cells with the conjugate for 30 minutes, assaying the cell and supernatant histamine and calculating the percentage release. This was found to be 66% with 2 ng of TMA-HSA.

Lymphocytes from the patient were stimulated with varying concentrations of TMA-HSA. Stimulation indices of tritiated thymidine incorporation were calculated by dividing the mean cpm of the stimulated cultures by the mean cpm of the

FIGURE 10 (continued)CASE HISTORY OF PATIENT WITH APPARENT RESPIRATORY ALLERGY
TO TRIMELLITIC ANHYDRIDE (TMA)

unstimulated cultures. The results are shown in the graph below. A stimulation index of greater than 2 was considered significant.



Lymphocyte reactivity in patient (x-x) , two other workers (o-o) & (●-●). Two control subjects have stimulation indices of less than 2 (□-□) & (■-■).

The immediate response is manifested by shortness of breath, wheezing and coughing occurring shortly after exposure this is followed several hours later by chills, malaise, chest tightness and dyspnea typical of the late reaction.

Trimellitic anhydride has given rise to immediate asthmatic reactions in some workers. A late reaction with symptoms resembling extrinsic allergic alveolitis is also recognised and a third response consisting of cough, (which may involve coughing up of blood) dyspnea with pulmonary infiltrates, a restrictive respiratory defect, hypoxaemia and anaemia (referred to as pulmonary-disease-anaemia syndrome) has been reported.³¹¹⁻³¹³ Immediate type asthma to pyromellitic dianhydride in exposed workers has also been found.¹⁴⁸

These anhydrides all have related chemical structures (table 5a) and consequently it is likely that the underlying mechanism responsible for the allergic reactions observed is similar.

5.3 Antigenic determinant

Anhydrides are reactive chemicals and readily form an amide or an imide linkage with amino groups of proteins. (See figure 7). It appears that the anhydride inhaled by exposed persons reacts with proteins in the respiratory tract (possibly in the respiratory secretion) to form conjugates which act as allergens. Sufficient quantities of the conjugate formed pass into the tissue spaces and blood stream and

come into contact with the cells of the immune system thereby initiating a response.

³⁸⁹ Studies on trimellitic anhydride (TMA) using human serum albumin and ovalbumin as carriers indicated that the likely antigenic determinant includes a portion of the protein as well as the trimellitic moiety. However, since both TMA conjugates reacted equally well with antibody it must be concluded that the part of the protein involved is quite small, possibly only 1 amino acid residue, which is common to both these proteins. Human serum albumin is a respiratory protein ovalbumin is not - consequently several other proteins in the body may also be able to act as carriers for the hapten.


It has been suggested that as many as 30 trimellitic anhydride residues may be attached to the human serum albumin molecule but whether 30 separate active sites are formed or only one is not clear. Probably 30 amino acid residues are available for combining with the trimellitic anhydride but only a few of these actually constitute active sites. Furthermore the sodium salt of TMA did not completely inhibit IgG antibody to TMA.³⁸⁹

However, immunologic studies on workers exposed to both trimellitic anhydride and phthalic anhydride have shown that the antibody responses elicited indicated little cross-reaction between the antibody directed against TMA-HSA or PA-HSA. This would infer that the -COOH group


FIGURE 11.

POSSIBLE STRUCTURES OF CONJUGATES WHICH WOULD BE FORMED BY
THE REACTION OF PHTHALIC ANHYDRIDE WITH THE EPSILON AMINO
GROUP OF LYSINE IN A PROTEIN MOLECULE.

1. IMIDE LINKAGE



2. AMIDE LINKAGE



of TMA is a key part of the antigenic determinant. It is also possible that this group reacts in vivo with other protein side chain groups to form a totally unrelated conjugate.

5.4 Reaction mechanisms

It seems likely from the clinical symptoms observed that both a type I and a type III reaction are involved in anhydride allergy although both may not be present in individual cases. Although immunological tests have not been undertaken in all reported cases the evidence obtained from those which have would seem to support this view. The initial reaction ^{probably involves} IgE antibody and the late one IgG. Indeed TMA-protein conjugates neutralised both types of antibody.

³⁰⁵
Lymphocyte transformation has been reported in some cases of apparent phthalic anhydride sensitisation inferring a cell mediated mechanism may also be involved. Whilst this has not been shown by other investigators studying respiratory sensitisation to anhydrides, cell-mediated (delayed) hypersensitivity is generally accepted as the causal mechanism for allergic contact eczema (dermatitis) and it is likely that workers developing dermatitis to anhydrides respond via this route.

³⁰⁷
Maccia et al demonstrated positive scratch tests in patients with respiratory sensitisation to phthalic anhydride after

application of both PA crystals and PA ethanol solution. Patch testing however gave negative results.

It is possible therefore that phthalic anhydride (and indeed other anhydrides) readily react with proteins in respiratory secretions or ~~in~~ in the subdermal tissue to form conjugates which act as antigens ^{the production of} for/humoral antibodies of both IgE and IgG classes ~~by~~ by locally circulating plasma cells. On the other hand, phthalic anhydride directly in contact with skin as experienced occupationally (or in patch testing) is likely to be in contact with different proteins and macromolecules and therefore to form a different type of conjugate. Such conjugates may penetrate the various skin layers in a different way (and possibly at a different rate) acting as an antigen which stimulates cellular antibody production thereby invoking a delayed type hypersensitivity response.

^{394;395}
Recent studies have implicated the Langerhans cell as 'an allergen trap' which absorbs haptens as they traverse the epidermis and converts them to complete antigens. Furthermore the close association between Langerhans and mononuclear cells in allergic contact dermatitis reactions suggests that they are involved in transferring antigen ³⁹⁶ recognition to T lymphocytes.

The reasons why an immediate respiratory reaction is invoked in some sensitised workers in contrast to a late

or dual response in others is not understood. Clearly the concentration of the agent, its physical form and the duration of exposure will be involved.

Most inhalant allergens in fact do not give rise to contact sensitivity. When they are injected they give rise to an immediate wheal and flare response which may be followed by a late reaction but not by a true delayed hypersensitivity reaction. The immediate response may remove all the effective antigen thereby³⁹⁷ not allowing a delayed response to be initiated. Evidence from animal studies has shown that immediate allergens injected with an antihistamine will give rise to delayed responses.

CONCLUSIONS AND RECOMMENDATIONS

6.1 Summary of Current Data

Reactive organic chemicals of low molecular weight capable of covalent bonding to groups on amino acid side chains of proteins present in the skin layers or in the respiratory tract are likely to give rise to allergic reactions in susceptible persons who are exposed to them.

The susceptible individual will become sensitised to the chemical at some stage during exposure but is unlikely to manifest any adverse symptoms at the time. Once sensitised the individual concerned will produce an allergic response to subsequent encounters with the chemical even at fairly low concentrations. A response is likely to be produced even if the method of presentation of the chemical in subsequent encounters is different from that initially.

The physical and chemical properties of the invading agent (and its constituents) will influence its site of entry to the body and therefore the likely proteins encountered with which conjugation may occur. Local metabolism of the chemical may occur, modifying its structure and therefore its protein binding ability.

The permeability and mobility generally of the hapten and the conjugate will influence whether only a localised response is triggered or circulating cells and antibodies

are encountered and a more generalised response invoked. Reactions involving cell mediated immunity in preference to those concerning humoral antibody are only likely to occur if the agent is encountered via the general skin layer rather than via the respiratory or gastrointestinal tracts. However, in certain circumstances both mechanisms may be involved.

The production of allergic contact dermatitis (generally cell mediated) rather than allergic asthma (humoral antibody mediated) when certain haptens are introduced to the hands as opposed to the respiratory tract highlights one of the fundamental points in occupational allergy. This key difference in reaction mechanisms is likely to stem from the differences in conjugates formed and the antigenic determinants produced. The accessibility of conjugates to circulating memory lymphocytes of the T and B classes is also likely to be of fundamental importance.

The antigenic determinant stimulating specific antibody production is likely to encompass parts of both the invading haptenic chemical and the carrier protein with which it is conjugated and need not be protein specific.

In the case of antibody mediated reactions both IgE and IgG are likely to be involved. The response produced and

the clinical symptoms observed will depend on the secondary mechanisms triggered by them whether complement is involved and on what other mediators or factors are released from co-operating leucocytes. IgE is associated with immediate (type I) reactions with IgG involved in the late (type III) reaction. Whilst these two reactions commonly occur together only one may be present in individual cases.

Irritant, pharmacological and possibly toxic effects of chemicals may swamp allergic responses in persons exposed to relatively high doses of agents to which they are sensitised. Even at fairly low concentrations the observed effects may not be entirely due to allergic mechanisms.

6.2 Sensitisation

Despite the advances in immunology and allergy over the past decades a full understanding of the mechanism of allergy has yet to be achieved. Several key questions require to be answered, the following two in particular :-

1. What predisposes a particular individual to become sensitised compared to others exposed to given potential allergens?
2. Once an individual is sensitised what control mechanisms operate to activate a particular response and symptoms rather than an alternative response which may be displayed by another individual in similar circumstances?

The reasons why certain individuals are susceptible to sensitisation to particular allergens is clearly inter-linked with the biological role of allergy generally.

Many studies have been undertaken to establish the reasons why allergy has developed. Current evidence ³⁹⁹ suggests that inhalant allergy in particular is a consequence of a genetically determined 'increased' level of local immunity.

Mast cells/basophils and IgE antibodies appear to provide a good defence mechanism against parasitic worms and this may have been an important reason for development of the response. In historical and evolutionary terms this advantage may have outweighed any possible disadvantage from inhalant allergies as currently experienced.

There is also evidence, ³⁹⁹ albeit inconclusive, to suggest that cancer patients (particularly those with tumours of mucosal surfaces) have a lower incidence of allergy. Such findings are consistent with the hypothesis that atopy is a consequence of a high level of mucosal immunity.

In the general population there are several different types of persons who do not experience allergic symptoms to a range of antigens:-

- i) Those who have not been exposed to a particular allergen.
- ii) Those who have been exposed, do not show symptoms or detectable signs at present and who never have had or never will do so.

- iii) Those who are going to develop symptoms in the future.
- iv) Those who have had allergic symptoms in the past but who have been 'spontaneously' cured.
- v) Those who have positive skin tests and detectable serum IgE antibody but deny any symptoms.

All these groups are often referred to as non-allergic and may be used in control studies when comparisons with allergic patients are made, although clearly they are not all necessarily non-sensitised persons. In cases of occupational allergy it is fairly easy to determine whether a given worker has been exposed to a particular allergen and therefore any asymptomatic exposed workers will fall into one of the categories ii), iii), iv) or v) above.

400

Current evidence suggests that delayed sensitisation and spontaneous cure appear to be antigen specific; that changes in the level of IgG and IgE antibodies generally occur in parallel and that spontaneous cure is not directly age related. Whether the length of allergic responses are in some way related to antigen dose is not known and clearly invites further study. A cellular mechanism for spontaneous cure and perhaps delayed sensitisation may operate involving suppressor T-cells switching off (or on) antibody response to a particular antigen.

Clearly the only truly non sensitised group will be those

falling into category ii) ie. exposed persons who are just non-responders. Further studies involving these persons in any study of exposed workers is essential if the phenomenon of sensitisation is to be elucidated.

6.3 Control Measures

The rapid development of technology currently occurring with an ever increasing demand for new products, particularly ^{Plastics} in the field, is undoubtedly provoking the widespread use of chemicals previously of little importance, and the continued synthesis of new chemicals. Since a significant proportion of these chemicals could be allergens such activities are likely to expose many workers to the risk of developing sensitisation, unless appropriate safeguards are taken. Prevention rather than treatment must remain the objective in dealing with occupational allergy, on the one hand by reducing contact with potentially harmful agents and on the other by selection and monitoring of those employed. Prediction of likely sensitisers before use is also important.

A summary of important control measures is given in Table 11. These methods are not mutually exclusive, the greatest benefit will be derived where several are used together.

Ideally substitution of known or suspected sensitisers with 'safer' alternatives is the best practice. However, for many important industrial chemicals there is no satisfactory alternative for the product available.

TABLE 11 : CONTROL MEASURES

1. SUBSTITUTION

- OF THE PARTICULAR SUBSTANCE
- OF THE PROCESS INVOLVED

2. ISOLATION (of the chemical from the worker)

- BY ENCLOSURE
- BY DISTANCE
- BY TIME

3. VENTILATION (of the working environment)

- GENERALLY BY DILUTION
- LOCAL EXHAUST SYSTEMS

4. PERSONAL PROTECTIVE EQUIPMENT

- GLOVES, OVERALLS, FOOTWEAR
- RESPIRATORY EQUIPMENT, MASKS

5. GOOD HOUSEKEEPING

- PREVENTION OF SPILLAGES, ACCUMULATIONS
- ROUTINE MAINTENANCE AND TESTING OF PLANT

6. TRAINING AND EDUCATION OF WORKERS

- ON PREVENTATIVE MEASURES, HAZARDS INVOLVED,
GOOD PRACTICES
- REPORTING OF PROBLEMS, SYMPTOMS

Furthermore questions of toxicity, flammability and explosion hazards will clearly outweigh sensitisation potential

when particular chemicals are considered. Of course the likelihood that a given chemical will give rise to sensitisation in exposed workers cannot be clearly predicted although obviously certain indications can be derived from animal studies and pre-screening of atopic subjects. When a particular chemical is found to be a significant sensitiser steps must be taken at that stage to consider whether it can be substituted before the problem develops further.

Wherever possible workers should be divorced from problem chemicals. In many cases reaction vessels, moulding machines etc. can be totally enclosed such that workers operating the process or the machine in question are isolated from the substances involved. Where enclosure is not total the greater the distance between the worker and the plant the better and the location of operating controls should reflect this. Isolation can also be achieved where workers do not enter hazardous areas until chemical reactions have been completed and thus the concentrations, temperatures etc. of particular chemicals will have been reduced.

Unfortunately whilst isolation of production workers can often be achieved other groups particularly maintenance, cleaning and inspection staff, by the very nature of their work, have to gain access to problem areas thereby requiring other control measures.

Airborne concentrations of harmful agents at the workplace can be reduced in most cases by efficient environmental control of dust and vapour. A suitable efficient and properly maintained extract ventilation of the workplace or more particularly as a local exhaust system, is an essential prerequisite. The use of personal protective equipment ranging from filter-type face masks (which are often inefficient, uncomfortable and not tolerated by workers) to positive pressure air hoods and full breathing apparatus will prevent (to varying degrees) inhalation of contaminated factory air. The wearing of appropriate gloves, overalls and boots is also important. Even the use of barrier creams is significant.⁴⁰¹ Complete isolation of workers from the substance in question with handling and observation through the wearing of special containment suits may have to be used in certain cases,⁴⁰² a practice well established where bio-hazards are concerned and in the nuclear industry.

Routine on-going monitoring of the workplace checking dust levels, particulate sizes, gaseous concentrations and related factors is vital to ensure that ventilation system provided is working satisfactorily and that other control measures are adequate. Such monitoring must clearly reflect the type of work undertaken and identify potential 'hot spots' in the workplace rather than merely establishing an average ambient level.^{403:404}

Defining a suitable reference level however, is virtually impossible and attempts must be made to obtain as low a concentration of the chemical as possible, preferably at a limit of the order of, or below that which can be detected by modern instrumentation. The introduction of Control Limits, Long Term Exposure Limits (LTEL), Short Term Exposure Limit (STEL) and other measures of 'safe' levels for particular chemicals has been an important step forward in controlling and restricting exposure to hazardous chemicals. However, such levels are principally designed to avoid workers developing acute or chronic conditions (eg. asphyxia, cancer) rather than in preventing sensitisation for which there is practically no safe level in susceptible individuals.

The principal basis for the determination of these limits is toxicity testing of the chemicals of animals and whilst this provides a background of information concerning potential acute and chronic effects on man, in the case of sensitisation and allergic response there are no established animal tests to screen for the existence of sensitising effect on humans. Even if sensitisation can be shown in particular animals there is no guide to its effect in man, indeed the reasons for one individual human being more susceptible to sensitisation than another are not understood. Structure and reactivity of given chemicals provide useful pointers as indicated in this study and more attention could beneficially be given to such matters.

However, in many industries the exact nature of the chemicals involved is often not known and cannot readily be predicted prior to the process starting.

Prevention of exposure must not be confined to the shop floor or stop at the factory gate. Any control measures adopted to protect front line workers must not give rise to hazards to other groups of persons (including the general public). The proper treatment and discharge of extract ventilation systems, the correct laundering of contaminated protective clothing, the safe disposal of both solid and liquid wastes and monitoring of the external environment are equally important. Cases of individuals not actively working with particular substances yet suffering allergic symptoms are not uncommon, and can often be traced to unsatisfactory conditions in these areas.

Transfer of potential allergens to workers clothes and the introduction of such agents into the home and other non-work environments can also pose serious problems. Exposure of the workers themselves is increased thereby prolonging the suffering of sensitised individuals beyond the working day. The likelihood of sensitisation developing in non-sensitised workers is increased and, more importantly, exposure of the worker's family to potential sensitisation and subsequent allergy can occur in such situations.

Comprehensive & continuing education and training of workers together with a high standard of occupational hygiene is essential to eliminate this. The problem is more difficult in non-industrial situations where washing and changing facilities may not be readily available and indeed where the exposed employees may actually work from home (eg. in forestry and farming.) It is imperative that the established attitudes, prevalent in some industries, that suffering is part of the job must be discarded.

6.4 Screening of Workers

Pre-screening of workers for susceptibility to sensitisation is clearly a desirable measure. ⁴⁰⁵ Unfortunately this is not as simple or advantageous as it might appear. The obtaining of medical questionnaires and patch testing using a specific batch of chemicals are established ways of identifying whether workers are atopic. Such procedures are often undertaken when workers are liable to be exposed to dermatitis problems. However, it appears that although an individual may be atopic he is not necessarily any more susceptible to respiratory sensitisation by a given agent than a non-atopic worker. Indeed non-atopic workers are often more susceptible. Furthermore susceptibility to sensitisation to a given agent does not automatically imply susceptibility to sensitisation by other agents. A greater understanding of the reasons why individuals are susceptible and the molecular basis of sensitisation are clearly important if predicting susceptibility and screening of workers is to be successful.

Notwithstanding these problems the routine monitoring of exposed workers is an important function to ensure signs and symptoms of sensitisation in individuals are identified at the earliest opportunity in order that steps can be taken to alleviate the individual's condition and improvements in the control measures operating can be instituted. ^{194; 406} The organisation and establishment of multidisciplinary occupational health services at workplaces are clearly fundamental to achieve this task and it is encouraging that many organisations now possess such units. Part time external medical advisers and consultants have a role to play but can never operate with the same effectiveness or provide the same expertise and commitment as an integral occupational health service.

By the time a patient presents with occupationally induced respiratory symptoms preventative measures have failed. It is also obvious that the most effective form of treatment is to remove the worker from the hazardous environment, or at least to relocate him in another part of the plant. In this instance social, financial and other implications must all be considered. Very often suitable alternative employment in areas away from the substance cannot be offered or the worker may refuse jobs for which he is unsuited or which carry lower pay. Premature retirement or dismissal on health grounds may be the only practical alternatives. In certain circumstances sensitised workers may continue to work and remain exposed to the allergen

concerned whilst undergoing some prophylactic treatment such as taking disodium cromoglycate. Clearly this latter course of action should not be taken lightly and may involve the worker in additional problems in the long term. (eg. asthma originally caused by sensitisation to a particular agent may develop into a non-specific form such that the sufferer experiences symptoms even when no longer exposed to the original agent.)

As indicated previously, a speedy correct diagnosis of the worker's complaint is essential. It must involve a review⁴⁰⁷ of the patient's past medical history, checking current activities (at work and elsewhere), and thorough medical examination and where possible bronchial challenge with suspected agents, skin testing and laboratory immunological studies. Cases where individuals initially suspected of being sensitised to a particular compound in the work situation subsequently, following more extensive investigation, being diagnosed as allergic to a totally unrelated substance are not uncommon. Once a single case of sensitisation to a given agent has been established in a particular workplace it is more imperative than before to ensure routine monitoring of the working environment is undertaken, that control measures are correctly operating (and where possible to extend them) and more importantly that regular medical screening and examination of exposed workers continues with the aim of identifying additional cases of sensitisation at the earliest stages.

6.5 Availability of Information

A large proportion of the published literature and current data is of little practical use in assessing the aetiology and pathogenesis of occupational allergy since basic immunological studies have not been undertaken in many cases. Provocation tests, determination of total and specific IgE antibody levels and similar studies are key operations which should and must be undertaken if unequivocal diagnosis of allergy is to be made and the causal agent clearly established. The continuing doubts and conflicting data in respect of an allergic mechanism for isocyanate asthma clearly illustrates this point. Whilst the immediate diagnosis of the patient's condition and its treatment must remain of prime concern this should not conflict with the wider objectives of obtaining all possible data relative to sensitisation to a given agent. Indeed the two tasks are mutually beneficial.

There is clearly a need for more liaison and interaction between the various disciplines and professions involved. Physicians intimately involved with the patients under their care often have little scope, inclination or opportunity to discuss individual problems with safety officers, engineers and factory management. Furthermore differences in emphasis, priorities and specialised knowledge amongst physicians can inhibit factory medical advisers, general practitioners, local hospital consultants and research academics from pooling resources and exchanging

ideas not only on individual problems but on the subject generally. Ultimately university and other research workers concentrating on immunological methods or animal studies are likely to become detached from the problems of industry and exposed workers.

Whilst the establishment of local occupational health services by many major employers is clearly an important development more special project teams and interdisciplinary research groups are essential if the full benefits of current knowledge and awareness are to be utilised in achieving good safe healthy working conditions. Bodies such as the Health and Safety Executive, the Employment Medical Advice Service, occupational health institutes as well as both employers and trades union organisations have important roles to play and must resolve their parochial, political and ideological differences if they are to be fully effective.

Obviously confidentiality on behalf of the patient (and his medical adviser) as well as the employer concerned is important not only in relation to legal and financial matters but also with regard to current public awareness and marketing considerations. Nevertheless such considerations must not inhibit the constructive beneficial dissemination of information which is so important in order to protect others.

Clearly all employers have both moral and legal duties to ensure that not only their workers but all persons likely to be affected by their business undertakings are safeguarded. Residents living in the immediate vicinity of industrial plants and the end users of particular products (including the general public) may all be unwittingly involved. Close liaison between factory operators and residents associations and also between manufacturers and consumer marketing organisations on such health matters is essential.

APPENDIX I

TESTS USED IN ALLERGY INVESTIGATIONS

SKIN TESTS

The two basic skin tests⁴⁰⁸ are the patch test (used principally for dermatitis investigation) and the prick test (used principally for asthma and rhinitis).

In the prick test a drop of reagent is placed on a clean dry healthy area of skin (the forearm is a convenient site) and a sharp needle is passed through it at a shallow angle superficially in the skin giving a slight lift to the skin, withdrawing the needle in a direction at right angles to the skin to produce a perceptible 'plink'. The reagent is blotted with a disposable tissue. It is estimated that approximately three ten-millionths of a ml. are introduced into the dermis by this technique. Reading takes place ten to twenty minutes later for maximal effect but delayed reactions may occur from 2 to 72 hours later.

A positive reading is a wheal 1mm or greater in diameter. There may be itching, a red flare and pseudopodial development. (indicative of a Type I, immediate reaction.)

The immediate response may run into a secondary oedematus reaction often strikingly raised above the surrounding skin and extensive, obvious after three to four hours and maximal after seven to eight hours. It is itchy and its borders are ill-defined. (Indicative of a Type III, Arthus reaction.)

At forty-eight to seventy-two hours after the secondary reaction has subsided, a third may occur that is erythematous and indurated. (Indicative of a Type IV, delayed reaction.)

The technique of patch testing is simply the application of the test material, in solution or solid on a piece of lint or linen 1cm^2 , to the skin - usually the back but sometimes the arm is used.

The patch test reactions are read at 48 hours after application although reactions may be positive earlier in cases of marked sensitivity. The reactions are graded from 0 to 4+ :-

- 0 no reaction
- 1+ erythema
- 2+ erythema, papules
- 3+ erythema, papules and vesicles
- 4+ marked oedema and vesicles.

Low grade reactions (0 to 1 or 2+) are probably not significant. A second reading is usually made ninety-six hours after application. Patch testing can be altered by the topical use of corticosteroids and systemic corticosteroid therapy may suppress most reactions thereby significantly affecting the results.

PROVOCATION TESTS

Whilst oral and nasal provocation tests are used in allergy investigations it is bronchial provocation testing which is a fundamental tool in occupational allergy and has been used extensively in the investigation of patients with asthma and extrinsic allergic alveolitis since 1947.

Bronchial provocation testing is routinely used to evaluate dusts, gases, vapours, and fumes suspected of causing occupational asthma and is also a useful method to monitor the effects of immunotherapy or the effectiveness of drugs. However, although a particular drug may alleviate bronchial response to allergen on provocation testing it may not be effective clinically. Provocation testing is normally undertaken in hospitals where remedial facilities and appropriate treatment are available should they prove necessary, although these tests are normally considered safe.

The principle method¹⁸⁰ used simulates work exposure to the particular agent and is carried out in an exposure chamber with adequate extraction facilities.

The allergen concerned may be presented in various ways dependant on its physical properties. For example grain and wood dust are best tested by the patient tipping

materials from one container to another whilst vapours from soldering fluxes are readily tested by the subject actually performing the soldering process.

Unfortunately with this test it is difficult to assess the dose of material inhaled by the patient. For many materials in the chamber, however, the concentration can be measured by air sampling and chemical analysis. Where possible the challenge concentration should reflect the known or suspected concentration encountered in the work environment. If the initial test proves negative it is repeated with concentrations 2 to 5 times greater (generally tests repeated at 10 min intervals) until result obtained. Duration of test - 15 to 30 minutes.

Respiratory function is measured 30 minutes and immediately before the bronchial provocation test and then every 5 minutes after the test for 1 hour and subsequently hourly for the rest of the day. It is essential that the tests commence early in the day so that sufficient observations can be made to detect the presence of a late reaction should one occur. Where a late reaction or extrinsic allergic alveolitis is likely to occur (predicted from case histories of the patient etc.) only 1 test per day is undertaken on subsequent days.

It is essential that all forms of medication which the patient may have been receiving are withheld for a period prior to bronchial provocation testing.

An alternative method for the test involves nebulised extracts of the allergen or pharmacological agent being inhaled by the subject through a special form of breathing apparatus. However, this bears little resemblance to natural exposure especially to those agents which normally occur in particle form and furthermore the dose, rate of exposure (rate of administration), presentation of allergen or the site of deposition within the respiratory tract is unlikely to be typical of occupational exposure.

A method of bronchial provocation testing using soluble antigens has been developed by Harries et al.⁴⁰⁹

The test material is inhaled as an aerosol from a Wright's nebuliser through a tight fitting face mask with an oxygen flow rate of 8 litres/minute. Respiratory function is measured every 5 minutes for 20 minutes before the test; every 10 minutes for 30 minutes after the test then hourly for the next 12 hours. A positive inhalation test is registered when a fall in FEV_1 of 15% or more (compared to the control day) occurs within 24 hours of the test or where a rise in temperature, malaise, leucocytoses, development of crackles in the lungs or a fall in transfer factor of 15% or more (compared to control day) occurs within 24 hours of the test.

RESPIRATORY FUNCTION TESTS ⁴¹⁰

These involve the measurement of various lung volumes and generally involve comparisons of the results obtained in healthy subjects with those in patients exhibiting respiratory symptoms especially in asthma.


The tests are carried out using various forms of recording spirometers. One of the commonest of these is the vitalograph, an instrument which measures the volume of gas expired during the period of exhalation (at ambient temperature and pressure) and records this against time on a chart. (See figure 12) The subject sits breathing into the apparatus by mouth with his nose sealed. He then takes a maximal inspiration and immediately breathes out forcefully, rapidly and completely as possible into the vitalograph.

The maximal volume of air that can be expelled in one second is called the Forced Expiratory Volume (FEV_1). This reflects the resistance offered by the airways (bronchioles, bronchi, trachea) to the expired air. The total volume expelled is the Vital Capacity (VC). These two records are normally expressed as a percentage ie. $\frac{FEV_1}{VC} \%$. In normal cases this figure is approximately 80% but it is decreased in patients with airways obstruction.

Vital Capacity is related to the size and development of the subject. (Usually 2.6 l/m^2 in males and 2.1 l/m^2 in females.) It is decreased in older people and in those suffering from

FIGURE 12.

RESPIRATORY FUNCTION TESTS (AN EXAMPLE OF A VITALOGRAPH
RECORDING)



$$\frac{\text{FEV}_1}{\text{VC}} \% = \frac{3.49}{4.51} = 77\%$$

certain respiratory diseases eg. polio, respiratory obstruction, pleural effusion, pneumothorax, pulmonary fibrosis, emphysema and pulmonary oedema.

Several other lung volumes and capacities (See figure 13) can also be determined by simple spirometry. The basic recording spirometer consists of a counter-balanced, inverted cylinder moving vertically inside a water-filled chamber so that a variable volume of air or gas is trapped under the cylinder. The cylinder is connected to a recording drum (Kymograph) such that when the lung volume increases in inspiration, the volume of the gas in the spirometer is reduced and the pen on the chart rises; conversely the pen falls with expiration.


The subject breathes through the mouthpiece in a closed circuit with the spirometer and his nose sealed. The instrument records the volume of air movement against time and a record of normal breathing and of deep inspiration and full expiration is made. The following lung volumes can then be calculated:-

- a) Tidal Volume (V_T) - the amount of gas inspired or expired during a single normal breath
- b) Inspiratory Reserve Volume (IRV) - maximal amount of gas that can be inspired after a normal inspiration
- c) Inspiratory Capacity (IC) = $IRV + V_T$
- d) Expiratory Reserve Volume (ERV) - maximal amount of gas expired from the end-expiratory position
- e) Vital Capacity (VC) = $IC + ERV$

FIGURE 13.

LUNG VOLUMES AND CAPACITIES

A representation of a recording obtained by a spirometer to illustrate the sub-divisions of the lung volume. The figures on the left are the average values for an adult man.



Measurements of Residual Volume (RV), Functional Residual Capacity (FRC) and the Total Lung Capacity (TLC) have to be determined by a separate technique - the closed circuit helium dilution method is often used. Residual volume may however be calculated using the following arbitrary formulae :-

$$\begin{aligned}\text{Males RV (ml)} &= 26 \times \text{age (years)} + \text{height (inches)} \\ &\quad - 11 \times \text{weight (pounds)} - 4570\end{aligned}$$

$$\text{Females RV (ml)} = 10 \times \text{age} + 1320$$

Hence $\text{FRC} = \text{ERV} + \text{RV}$ and $\text{TLC} = \text{VC} + \text{RV}$

LABORATORY TESTS

Determination of total serum IgE, a routine clinical procedure, is normally undertaken by a form of Radio-immunoassay (eg.) the Double antibody inhibition radio-immunoassay or the Radioimmunosorbent technique (RIST). These tests which are fairly sensitive involve antibody-antigen interaction in which one of the reactants has been labelled with an appropriate radioactive isotope. The key step involves competition between labelled and unlabelled forms of one reactant (in this case IgE) for binding sites on the other reactant (anti IgE). The labelled antigen is usually present in slight excess over the antibody. Since the capacity of antibody to bind antigen is limited addition of serum containing unlabelled antigen will cause a decrease in the amount of labelled antigen that is bound.

In the double antibody inhibition RIA the test serum is mixed with rabbit anti-IgE and the radiolabelled IgE added. Goat anti-rabbit is then added to precipitate the rabbit immunoglobulin and after washing the radioactivity in the precipitate is counted.

The RIST uses a solid phase for one of the reactants therefore a second antibody is not required. Particles of activated cellulose or similar material are used to bind anti-IgE preparation. The mixture is then centrifuged, washed and the radioactivity on the immunosorbent counted. The amount of label bound to the insolubilised antibody is therefore inversely proportional to the amount of IgE

in the test serum.

The quantity of IgE present in the test serum can then be found by reference to a 'standard curve' (ie.) a graph showing the percentage of labelled IgE bound as a function of the amount of unlabelled IgE present. The curve having been constructed from data obtained by performing the assay using samples of unlabelled serum in which the concentration of IgE present is known.

The Radioallergosorbent Test (R.A.S.T.)

The level of antigen-specific IgE can be determined by this method. Specific allergen is coupled with an insoluble matrix (eg. cellulose beads) and the particles allowed to react with the test serum. IgE antibody with specificity for the coupled antigen will bind to the particles. A further incubation is performed by adding radiolabelled anti-IgE. The percentage of the added counts bound to the matrix is a measure of the antigen-specific IgE in the test serum.

RAST correlates quite well with clinical allergy but precise correlation with skin tests awaits antigen standardisation. Clinical scores are obtained by comparison with RAST results with strongly positive reaginic sera: A 4+ RAST precipitates as much radio-labelled antibody to IgE as does a 1:1 dilution of reference sera; a 2+ RAST

precipitates as much as a 1:4 to 1:25 dilution and a negative RAST indicates less reactivity than a 1:50 dilution of reference sera. False positive results are rare with this technique. Clinically the RAST may provide an alternative to skin tests in persons with dermographism or severe dermatitis, in apprehensive adults or small children.

Furthermore the RAST allows a safe diagnostic approach when intradermal (eg. bee sting) or provocation tests may be hazardous, or when the withdrawal of drugs (eg. anti-histamines) inconveniences the patient. Another advantage is the possibility of being able to study physiological fluids other than serum (gut or nasopharyngeal secretions for example). The fluids could be stored, as could serum, for future analysis at a convenient time.

The RAST has been useful in demonstrating IgE antibody to such diverse agents as ragweed, grass, pollens, nuts, Hymenoptera extracts, insulin and the penicilloyl antigens of penicillin.

Red-cell linked antigen-antiglobulin reaction (RCLAAR)

This technique makes use of red blood cells as indicator particles. Red cells are ideal indicators of antigen-antibody interactions because they are less liable to adsorb proteins non-specifically than are other indicators.

The antigen is first coupled to rabbit antibody directed against the red cells (the use of this reagent prevents excessive disturbance of the red cell membrane and clumping which would occur if the antigen was coupled to them direct.) The reagent formed when incubated with the indicator cells links to them by means of the antibody without damage of the membrane. If the cells coupled to the reagent are then incubated with serum containing antibody with specificity for the coupled antigen combination takes place. Antiglobulin specific for the heavy chains of the antibody used is added to agglutinate the red cells. (This enables specific antibody of IgE, IgG and other immunoglobulin classes to be separately determined.)

Antigen binding radioimmunoassay (or radioimmunoprecipitation)

A technique which enables IgG, IgA and IgE antibody in a given serum sample to be determined in parallel. Using low concentrations of allergen the relationship between different classes of antibody is accurately reflected. Furthermore since in vivo exposure to allergens is probably at low concentration antibodies measured in the presence of low concentrations may reflect the biologically relevant antibody.

Serum samples are incubated with radiolabelled allergen and carrier protein for 4 hours. Goat anti-IgE (or IgG or IgA) is added and left overnight to precipitate then the precipitate is washed and the radioactivity counted.

The count is directly related to the quantity of specific immunoglobulin in the serum.

The assay however requires large quantities of IgE and IgE myeloma serum (as carrier protein) and so is not normally used in preference to RAST for routine IgE determination.

APPENDIX IIGLOSSARY

ANAEMIA Bloodlessness - in particular shortage of haemoglobin in red blood cells characterised by signs and symptoms of oxygen lack.

ANAPHYLAXIS An extreme form of allergy whereby the subject reacts very sharply. In severe cases the bronchi go into spasm and death may result unless prompt treatment with adrenalin is given. Commonly used to mean a type 1 allergic reaction.

ASTHMA A respiratory disease characterised by recurrent attacks of difficulty in breathing usually accompanied by wheezing, cough and a sense of constriction of the chest. It is due to spasm of the muscular fibres in the walls of the bronchioles reducing the size of the airway and impeding respiratory airflow especially when breathing in.

ATOPY The capacity of an individual to develop type 1 allergy to common environmental materials which is demonstrable by skin or serological tests without necessarily being linked to the presence of clinical symptoms. It appears to be hereditary and involves genetic factors but is not fully understood.

BASOPHIL A type of white blood cell containing granules which stain blue/black. They are found in much fewer numbers than either neutrophils or eosinophils. Their function is poorly understood but they are implicated in histamine release in immediate type hypersensitivity - analogous to that found with mast cells.

BRADYKININ A polypeptide that causes the walls of blood vessels near the site of an injury to be more permeable allowing fluid to escape into the tissues. It is also capable of inducing contraction of smooth (involuntary) muscles.

CEILING LIMIT A term used when defining occupational exposure limits, (sometimes referred to as the Threshold Limit Value-Ceiling) indicating the concentration that should not be exceeded even momentarily.

CONTROL LIMIT The level of an airborne contaminant, averaged over a specific time period, above which personal exposure is considered to be unacceptable.

DISODIUM CROMOGLYCATE A non-corticosteroid drug which inhibits the release of histamine and SRS-A from sensitised human lung. It is not antagonist of histamine or SRS-A and is not anti-inflammatory. Effective in many patients in preventing but not reversing experimentally induced allergic or exercise associated asthma.

DYSпноEA Undue breathlessness and abnormal awareness of the effort of breathing.

EOSINOPHILS White blood cells containing large granules readily stained with the red dye eosin which originate from the bone marrow. Increase in the concentration of these cells above 4% of the total white blood cell numbers occurs in several conditions including some allergies. They accumulate at the sites of antigen/antibody reaction in response to specific chemotactic factors liberated locally. Immune reactions involving IgE are particularly likely to attract eosinophils. They are implicated in processing and cell to cell transfer of antigen breakdown products and their phagocytic potential is well documented.

ERYTHEMA Abnormal reddening of the skin. Erythema with rise in temperature generally heralds onset of fever whereas erythema without rise in temperature is most commonly the result of allergy.

HEMOPTYSIS Coughing up of blood from some part of the respiratory tract.

INDURATED Hardened or calloused.

LICHENIFICATION An area of thickened and hardened skin in which the normal skin markings are visibly accentuated. This condition is usually due to chronic inflammation resulting from scratching.

LYMPHOCYTE A type of white blood cell (leucocyte)

involved in adaptive immune responses particularly in the recognition of antigen and the specificity of all responses made against it. Small lymphocytes carry the information for binding to antigen and a vast number of different specificities exist in the whole lymphocyte population. They are capable of several quite distinct activities ranging from the ability to differentiate into antibody producing cells to being cells directly involved in cell-mediated immunity. Two distinct types are found: the so called Bcells from the bone marrow involved in antibody production, and the T cells which develop under the influence of the thymus gland and are involved in cell mediated immunity. Cooperation between the two types occurs in several reactions.

LYMPHOKINES Chemical substances which affect certain types of cell (including macrophages and various white blood cells) in a multitude of ways in order to augment a particular immune response. Commonly secreted by lymphocytes.

MACROPHAGES Large cells circulating in normal individuals, capable of carrying out several functions. One of the most important of these being phagocytosis - ingestion and digestion of foreign material. They contain packets of enzymes capable of bringing about proteolysis of such material.

MAST CELLS Cells found in connective tissue filled with coarse granules. They secrete heparin (anti-clotting

agent of blood) and histamine. Release of histamine in particular is triggered in type 1 allergic reactions by a mechanism not fully understood but which involves binding of IgE antibody to receptors on the cell prior to antigen/antibody reaction. Histamine release can be initiated by other mechanisms involving mechanical or chemical irritation.

NEUTROPHILS Phagocytic cells present in the blood, more motile and effective phagocytes than macrophages. Neutrophils form one of the first lines of defence in the body being one of the first cells to arrive on the scene in large numbers at the site of entry of foreign material into the body. They may be attracted towards target material by chemotaxis.

OEDEMA Abnormal accumulation of watery fluid in the body tissues and cavities.

PAPULE A pimple or small projection raised above the surface of the surrounding skin. Hence PAPILLARY.

PHAGOCYTOSIS The process of ingestion and digestion of foreign material by certain cells, principally macrophages and neutrophils. Phagocytosis occurs throughout the body but the liver is a principal site. An important part of native immunity as well as in specific reactions of adaptive immunity.

PROPERDIN A protein present in the serum and body fluids participating in the complex system of natural immunity. Its activities include bactericidal action against gram-negative bacteria, neutralisation of some viruses and protection against fatal radiation sickness.

PROSTAGLANDINS A series of related fatty acids found in various parts of the body and which act as local hormones. They have the ability to lower blood pressure and can inhibit the activity of catecholamines in mobilising free fatty acids.

PRURITIC Irritant or itchy.

PSORIASIS A fairly common skin disease characterised by the formation of red patches which are covered by fine silvery scales. Hence PSORIASIFORM.

PURULENT Containing or discharging pus.

RHINITIS The generic term for inflammation of the mucous tissue of the nose. When it is allergic in origin it is usually referred to as hay fever. The symptoms are sneezing, rhinorrhea, nasal obstruction and itching of the nose, palate and pharynx.

SHORT TERM EXPOSURE LIMIT (STEL) An occupational exposure limit aimed primarily at avoiding acute effects or at least reducing the risk of occurrence. They are normally expressed as 10 minute time weighted average (TWA) concentration. The units being parts per million (ppm) or milligrams per cubic metre of air (mg/m^3). These limits are considered to represent good practice and realistic criteria for the control of exposure, plant design, engineering controls and, if necessary, the selection and use of personal protective equipment. STEL and Long Term Exposure Limits (LTEL) are listed for a large range of materials in a Health & Safety Executive Guidance Note. Sensitised individuals may well react to exposure to minute levels of substances (acting as allergens) well below these listed concentrations.

LONG TERM EXPOSURE LIMIT (LTEL) An occupational exposure limit concerned with the total intake over long periods intended to protect against the effects of long term exposure or reducing the risks to an insignificant level. They are normally expressed as 8 hour time weighted average concentrations.

URTICARIA An allergic condition characterised by the rapid appearance of weals and blisters on the skin usually lasting for only a few hours and accompanied by intense itching. Thought to be due to release of histamine leading to raised vascular permeability and local accumulation of fluid in the dermis of the skin. Urticaria may also be produced by non-immune reactions.

VASODILATION Expansion of a blood vessel. (Reverse referred to as vasoconstriction.)

VESICLES Small blisters occurring as an eruption on the skin or mucous membrane conventionally not larger than a pea. The horny layer of the skin is raised by exudation of clear or turbid fluid to form a rough hemispherical protrusion sometimes surrounded by a red inflamed zone. Hence VESICULAR.

APPENDIX III

REFERENCES AND BIBLIOGRAPHY

1. Schilling, R.S.F. (1981) in Occupational Health Practice
Schilling, R.S.F. (Ed) 2 Edn. pp 3-26 (Butterworths).
2. Ramazzini, B. (1713) De Morbis Artificum Diatriba
(translated 1940) Wright, W.C. Diseases of workers 1713
(Chicago University Press).
3. Hunter, D. (1978) Diseases of occupations. 6th Edn.
(Hodder & Stoughton).
4. Cmnd. 8121 (1981) Occupational Asthma, Report of the
Industrial Injuries Advisory Council, (HMSO).
5. DHSS Booklet NI 237 (March 1982) Occupational Asthma.
6. Industrial Injuries Advisory Council
Personal communication.
7. Harrington, M. (1981) Epidemiology.
HEALTH AND SAFETY AT WORK Aug 1981 36-39
8. Flindt, M.L.H. (1969) Pulmonary disease due to
inhalation of derivatives of Bacillus subtilis enzyme
preparations. LANCET 1 1177-1181
9. Davies, R.J., Pepys, J. (1977)
Asthma p190
10. Anwar, A.R.E., Kay, A.B. (1977) Membrane receptors for
IgG and complement on human eosinophils and neutrophils
and their relation to eosinophilia.
J IMMUNOLOGY 119 976
11. Goldstein, A. et al (1974)
FED PROC 33 2053
12. Burnett, F.M. (1957) A modification of Jerne's theory
of Antibody production using the concept of clonal
selection. AUS J SCI 20 67

13. Pepys, J., Edwards, A.M. (1979) The Mast Cell: its role in health and disease (Pitman).
14. Plant, M., Lichenstein, L.M. (1983) Cellular and chemical basis of the allergic inflammatory response. In 'Allergy: principles and practice' Middleton, E., Reed, C.E. & Ellis, E.F. 2nd Edn. pp 119-146 (C. V. Mosby & Co.)
15. Coombs, R.R.A., Gell, P.G.H. (1968) Classification of allergic reactions. In 'Clinical Aspects of Immunology' Gell, P.G.H., Coombs, R.R.A. (Eds.) 2nd Edn. (Blackwell Scientific Publications.)
16. Von Pirquet, C. (1906) ALLERGIE MUNCHEN WOCHNSCHR 54 1457
17. Pepys, J. (1977) Clinical and therapeutic significance of the pattern of allergic reactions of the lungs to extrinsic agents. AMER REV RESP DIS 116 573-588
18. Pepys, J. (1975) 'Atopy' in 'Clinical Aspects of Immunology' Gell, P.G.H., Coombs, R.R.A., Lachman, P.J. (Eds,) 3rd Edn. p877 (Blackwell Scientific Publications).
19. Newhouse, M.L., Tagg, B. et al (1970) An epidemiological study of workers producing enzyme washing powders. LANCET 1 689
20. Greenberg, M., Milne, J.F., Watt, H. (1970) Survey of workers exposed to dusts and derivatives of B. subtilis BRIT MED J 2 629
21. Pepys, J. (1977) Allergy to platinum compounds' in Medical and Biologic Effects of Environmental Pollutants Platinum-Group Metals Chptr. 7., Proceedings National Academy of Science 105 Washington.

22. Takahashi, M., Czae, J et al (1976) Mechanism of solubilisation of immune aggregates by complement: implications for immunopathy TRANSPLANT REV 32 121
23. Pepys, J. et al (1972) Asthma due to inhaled chemical agents: TDI
CLIN ALLERGY 2 225-236
24. Askenase, P (1977) Role of basophils, mast cells & vasoamines in hypersensitivity reactions with a delayed time course. PROG ALLERGY 23 199
25. Dvorak, H.F., Mimm, M.C., Dvorak, A.M. (1976)
Morphology of delayed type hypersensitivity reactions in man. J. INVEST DERMATOL 67 391
26. Thomas, W.R., Asherson, G.L., Watkins, M.C. (1976)
Reaginic antibody produced in mice with contact sensitivity. J. EXP MED 144 1386
27. Michaelsson, G., Juhlin, L. (1973) Urticaria induced by preservatives and dye additives in food and drugs
Br J DERMATOL 88 525-532
28. Cronin, E. (1972) Contact Dermatitis XVII : Reactions to contact allergens given orally or systemically.
Br J DERMATOL 86 104
29. Mitchell, J.C. (1971) The skin & chemical additives to foods. ARCH DERMATOL 104 329
30. Chetty, A (1982) Extrinsic Allergic Alveolitis due to milk allergy: case report & review of the literature.
ANN ALLERGY 48 113
31. Pepys, J. (1982) Occupational allergy: an overview
J OCCUP MED 24 534-538

32. Kaltreider, H.B. (1973) Hypersensitivity pneumonitis: immunologically mediated lung disease resulting from the inhalation of organic antigens. J. OCCUP MED 15 949
33. Guidance Note EH 26 (1981) Occupational Skin Diseases: Health & Safety precautions (Health & Safety Executive).
34. Friedlaender, M.H. (1979) Allergy & Immunology of the Eye. (Harper and Row).
35. Muir, D.C.F. (1972) Clinical aspects of inhaled particles. (Heinemann).
36. Coca, A.F., Cooke, R.A. (1923) On the classification of the phenomenon of hypersensitivities.
J. IMMUNOLOGY 8 163
37. Fawcett, I.W. et al (1977) Asthma due to inhaled chemical agents: epoxy resin systems containing phthalic acid anhydride, trimellitic acid anhydride & triethylene tetramine. CLIN ALLERGY 7 1-14
38. Bruckner, H.C. et al (1968) Clinical and immunological appraisal of workers exposed to di-isocyanates.
ARCH ENVIRON HEALTH 16 619-625
39. Gandevia, B. (1963) Studies of ventilatory capacity and histamine response during exposure to isocyanate vapour in polyurethane foam manufacture.
BRIT J IND MED 20 204-209
40. Gandevia, B. (1974) Pulmonary reactions to organic chemicals: Clinical history, physical examination and X-ray changes. ANN NY ACAD SCI 221 10-26
41. (1966) Polyoxyphenols of Western Red Cedar: structure of plicatic acid. CAN J CHEM 44 52
42. Lincoln, T.A., Bolton, N.E., Garrett, A.S. (Jr) (1974) Occupational allergy to animal dander & sera.
J OCCUP MED 16 465

42. Lincoln, T.A., Bolton, N.E., Garrett, A.S. (Jr) (1974)
Occupational allergy to animal dander & sera.
J OCCUP MED 16 465
43. Newman Taylor, A.J. (1982) Laboratory animal allergy.
EUR J RESP DIS 63 Suppl 123 60-64
44. Sorrel, A., Gottesman, J. (1957) Mouse allergy
ANN ALLERGY 15 662
45. Rajka, G. (1961) Ten cases of occupational
hypersensitivity to laboratory animals.
ACTA ALLERG 16 168-176
46. Arbesman, C.E. et al (1958) Sensitivity to animals:
A case report with immunologic studies.
J ALLERGY 29 129-183
47. Prahl, P., Roed-Petersen, J. (1979) Type I allergy from
cows in vet surgeons. CONTACT DERM 5 33
48. Carroll, K.B., Pepys, J. et al (1975) Extrinsic allergic
alveolitis due to rat serum proteins.
CLIN ALLERGY 5 443
49. Taylor, A.N. et al (1977) Respiratory allergy to urine
protein of rats & mice. LANCET 2 847
50. Burge, P.S., Edge, G.M. et al (1980) Occupational asthma
in a research centre breeding locusts.
CLIN ALLERGY 10 355
51. Cuthbert, D.D., Brostoff, J. et al (1979) Barn allergy:
Asthma & rhinitis due to storage mites.
CLIN ALLERGY 9 229
52. Feinberg, A.R., Feinberg, S.M., Benaim-Pinto, C. (1956)
Asthma & rhinitis from insect allergens.
J ALLERGY 27 437

53. Frankland,A.W., Lunn,J.A. (1965) Asthma caused by the grain weevil. B J IND MED 22 157
54. Stevenson,D.D., Mathews,K.P. (1967) Occupational asthma following inhalation of moth particles. J ALLERGY 39 274
55. Frankland,A.W. (1953) Locust sensitivity.
ANN ALLERGY 11 445
56. Ancona,G. (1923) An epidemic of asthma due to *Pediculoides ventricosus* II POLICLINICO 30 1
57. Lunn,J.A. (1966) Millworkers asthma: allergic responses to the grain weevil. B J IND MED 23 149
58. Cabanien,G. et al (1971) A study of precipitating antibody in allergy to *Ephestia Kuehniella*
REVUE FRANCAISE D'ALLERGIE 11 257
59. Cuthbert,O.D. (1978) Agriculture Acarina & Allergy
Proceedings 3rd Charles Blackley Symposium.
60. Wittich,F.W. (1940) Allergic rhinitis & asthma due to sensitisation to the Mexican bean weevil (*Zabrotes subfasciatus boh*). J ALLERGY 12 42
61. Ordman,B. (1946) Sewage filter flies (*Psychoda*) as a cause of bronchial asthma. SOUTH AFRICA MED J 20 32-35
62. Lunn,J.A., Hughes,D.T.D. (1967) Pulmonary hypersensitivity to the grain weevil. BRIT J IND MED 24 158
63. Brooks,S.M. (1977) Bronchial asthma of occupational origin. SCAN J WORK ENVIRON HEALTH 3 53
64. Freedman,S.O. (1966) Allergic & toxic mechanisms in occupational lung disease. MOD TREATMENT 3 838
65. Bjorksten,F., Backman,A. et al (1977) Immunoglobulin E specific to wheat & rye flour proteins.
CLIN ALLERGY 7 473

66. Hendrick,D.J., Davies,R.J., Pepys,J. (1976) Baker's Asthma. CLIN ALLERGY 6 241
67. Bouhuys,A. (1974) Breathing, Physiology, Environment & Lung Disease p416 (Grune & Stratton).
68. Leach,J. (1863) LANCET 2 648
69. Figley,K.D., Elrod,R.M. (1928) Endemic asthma due to castor bean dust. J AMER MED ASSOC 90 79
70. Topping,M.D. et al (1982) Castor bean allergy amongst workers in the felt industry. ALLERGY 37 603-608
71. Davies,R.J., Green,M., Schofield,N.M^C. (1976) Reccurent nocturnal asthma after exposure to grain dust. AMER REV RESP DIS 114 1011
72. Lybarger,J.A. (1981) Occupational asthma induced by inhalation & ingestion of garlic. J ALLERGY CLIN IMMUNOL 69 448
73. Falleroni,A.E. et al (1981) Occupational asthma secondary to inhalation of garlic dust. J ALLERGY CLIN IMMUNOL 68 156
74. Henson,G.E. (1940) Garlic: an Occupational factor in the aetiology of bronchial asthma. J FLA MED ASSOC 27 86
75. Fowler,P.B.S. (1952) Printer'S asthma. LANCET 2 755
76. Bush,R.K., Cohen,M. (1977) Immediate & late onset asthma from occupational exposure to soybean dust. CLIN ALLERGY 7 369
77. Gandevia,B., Milne,J. (1970) Occupational asthma & rhinitis due to Western Red Cedar (thuja plicata) with special reference to bronchial reactivity. B J IND MED 27 235

78. Milne, J., Gandevia, B. (1969) Occupational asthma & rhinitis due to Western Red Cedar. MED J AUST 2 741
79. ChangYeung, M. et al (1982) Clinical features & natural history of occupational asthma to Western Red Cedar. A J MED 72 411
80. Doig, A.T. (1949) POSTGRAD MED J 25 639
81. Ishizaki, T. et al (1973) Occupational asthma from Western Red Cedar dust in furniture factory workers. J OCCUP MED 15 580
82. Chang -Yeung, M. et al (1973) Occupational asthma & rhinitis due to Western Red Cedar (Thuja plicata). AMER REV RESP DIS 108 1094
83. Chang-Yeung, M. et al (1971) Bronchial reaction to Western Red Cedar (Thuja Plicata). CAN MED ASS J 105 56
84. Chang-Yeung, M. et al (1978) A respiratory survey of Cedar mill workers: Prevelance of symptoms & Pulmonary Function Abnormalities. J OCCUP MED 20 323
85. Pajgiaro, P.L. et al (1981) Bronchial asthma due to inhaled wood dust Tanganyika aningre. CLIN ALLERGY 11 605
86. Orsler, R.J. (1979) Health problems associated with wood processing BUILDING RESEARCH ESTABLISHMENT Information paper.
87. Hausen, B.M. (1981) Woods injurious to human health: on the toxic, irritant, sensitising & carcinogenic properties of commercial timbers. (W de Gruyter).

88. de Jong, J.C. et al (1951) Eczema due to the wood of Peroba do campos : isolation of the allergen.
ACTA DERM VENEREOL 31 108
89. Pickering, C.A.C., Balten, J.C., Pepys, J. (1972) Asthma due to inhaled wood dusts, Western red cedar & iroko.
CLIN ALLERGY 2 213
90. Sosman, A.J., Schlueter, D.P. et al (1969) Hypersensitivity to wood dust. N ENGL J MED 281 977
91. Ordman, D. (1949) Bronchial asthma caused by the inhalation of wood dust. ANN ALLERGY 7 492
92. Ordman, D. (1949) Wood dust as an inhalant allergen: Bronchial asthma caused by kejaat wood (pterocarpus auqolensis) S AFR MED J 23 973
93. Burge, P.S. et al (1979) Occupational asthma in an electronics factory. THORAX 34 13-18
94. Burge, P.S. et al (1979) Occupational asthma in an electronics factory: a case control study to evaluate aetiological factors. THORAX 34 300-307
95. Burge, P.S. et al (1980) Bronchial provocation studies in workers exposed to the fumes of electronic soldering fluxes. CLIN ALLERGY 10 137
96. So, S.Y., Lam, W.K., Yu, D. (1981) Colophony induced asthma in a poultry vendor. CLIN ALLERGY 11 395
97. Burge, P.S. (1982) Occupational asthma in electronic workers caused by colophony fumes: follow up of affected workers. THORAX 37 348
98. Burge, P.S. (1978) Occupational asthma in the electronics industry. OCCUP HEALTH 30 411

99. Burge, P.S. et al (1978) Respiratory disease in workers exposed to solder flux fumes containing colophony (pine resin). CLIN ALLERGY 8 1-14
100. Fawcett, I.W. et al (1976) Asthma due to inhaled chemical fumes from multicore soldering flux and colophony resin. CLIN ALLERGY 6 577-585
101. Dolevich, J., Shaikh, W. et al (1977) Human exposure and sensitisation to airborne papain. ANN ALLERGY 38 94
102. Tarho, S.M. et al (1978) Papain induced allergic reactions. CLIN ALLERGY 8 207-216
103. Novey, H.S. et al (1979) Papain induced asthma: physiological & immunological features.
J ALLERGY CLIN IMMUNOL 63 98
104. Karr, R.M., Lelver, S.B et al (1978) Coffee workers asthma: a clinical appraisal using the RAST.
J ALLERGY CLIN IMMUNOL 62 143
105. Freedman, S.O. et al (1961) Chlorogenic acid: an allergen in green coffee beans. NATURE 192 241
106. Jones, R.W. (1982) Lung function consequences of exposure and hypersensitivity in workers who process green coffee beans. AMER REV RESP DIS 125 199
107. Starr, J.C. et al (1982) Immediate type I asthmatic response to Henna following occupational exposure in hairdressers. ANN ALLERGY 48 98-99
108. Pepys, J. et al (1976) Asthma due to inhaled chemical agents: persulphate salts & henna in hairdressers.
CLIN ALLERGY 6 399-404
109. Symington, I.S. et al (1981) Type I allergy in mushroom soup processors. CLIN ALLERGY 11 43

110. Galleguillos, F., Rodriguez, J.C. (1978) Asthma caused by bromelain inhalation. CLIN ALLERGY 8 21
111. Baur, X., Fruhmann, G. (1979) Allergic reactions including asthma to the pineapple protease bromelain following occupational exposure. CLIN ALLERGY 9 443
112. Muittari, . et al (1978) Natural & synthetic fibres as causes of asthma & rhinitis. ANN ALLERGY 41 48-50
113. Popa, V., Gavrilescu, N., Prada, N. et al (1969) An investigation of allergy in byssinosis: sensitisation to cotton, hemp, flax & jute antigens.
Br J IND MED 26 101-108
114. Cambell, J.A., Kryda, M.J., et al (1983) Cheese workers hypersensitivity pneumonitis penicillium roqueforti
AMER REV RESP DIS 127 495-496
115. Pepys, J., Jenkins, P.A. et al (1963) Farmer's Lung: Thermophilic actinomycetes as a source of 'farmer's lung hay antigen. LANCET 2 607
116. Ghose, T., Landrian, R. (1974) Immunopathological studies in patients with farmer's lung.
CLIN ALLERGY 4 119
117. Pepys, J. (1969) Hypersensitivity diseases of the lung due to fungi & organic dusts.
Monographs of Allergy 4 (S. Karger).
118. Salvaggio, J.E. et al (1967) Bagassosis: Demonstration of precipitins against extracts of thermophilic actinomycetes in sera of affected individuals.
J ALLERGY 39 106
119. McCarthy, D.S., Pepys, J. (1971) Allergic broncho-pulmonary aspergillosis Clinical immunology 1. Clinical factors. CLIN ALLERGY 1 261

120. McCarthy,D.S., Pepys,J. (1971) Allergic broncho-pulmonary aspergillosis Clinical immunology 2. Skin nasal & bronchial tests. CLIN ALLERGY 1 415
121. Malo,J.L., Hawkins,R., Pepys,J. (1977) Studies in chronic allergic bronchopulmonary aspergillosis:
1. Clinical and physiological findings.
THORAX 32 254
122. Malo,J.L., Inouye,T. et al (1977) Studies in chronic allergic bronchopulmonary aspergillosis: 4. Comparison with group of asthmatics. THORAX 33 275
123. Safirstein,B.H., D'Souza,M.F. et al (1973) Five year follow up of allergic pulmonary aspergillosis.
AMER REV RESP DIS 108 450
124. Chan Yeung,M., Chase,W.H., Trapp,W. (1971) Allergic bronchio aspergillosis clinical & pathologic study of 3 cases. CHEST 59 33
125. Pepys,J., Wells,I.D., D'Souza,M.F. et al (1973)
Clinical & immunological responses to enzymes of Bacillus subtilis in factory workers & consumers.
CLIN ALLERGY 3 143
126. Newhouse,M.L., Tagg,B. et al (1970) An epidemiological study of workers producing enzyme washing powders.
LANCET 1 689
127. Juniper,C.P., How,M.S. et al (1977) Bacillus subtilis enzymes: a 7 year clinical, epidemiological and immunological study. J SOC OCCUP MED 27 3-12
128. Franz,T., McMurrair,K.K. et al (1971) Clinical, immunologic and physiological observations in factory workers exposed to B.subtilis enzyme dust.
J ALLERGY 42 170

129. Mitchell,C.A., Gandevia,B. (1971) Respiratory symptoms and skin reactivity in workers exposed to proteolytic enzymes in the detergent industry.
AMER REV RESP DIS 104 1
130. Pepys,J., Longbottom,L. et al (1959) Allergic reactions of the lungs to enzymes of Bacillus subtilis.
LANCET 1 1181
131. Weill,H., Waddell,L.C., Ziskind,M. (1971) A study of workers exposed to dusts containing derivatives of Bacillus subtilis. J AMER MED ASSOC 217 425
132. Davies,R.J., Hendrick,D.J., Pepys,J. (1974) Asthma due to inhaled chemical agents: ampicillin,Benzyl penicillium 6 amino penicillamic acid and related substances.
CLIN ALLERGY 4 227
133. Davies,R.J., Pepys,J. (1975) Asthma due to inhaled chemical agents: the macrolide antibiotic spiramycin.
CLIN ALLERGY 5 99
134. Hunter,D., Milton,R., Perry,K.M.A. (1945) Asthma caused by the complex salts of platinum.
BR J IND MED 2 92
135. Cromwell,O., Pepys,J. et al (1979) Specific IgE antibody to platinum salts in sensitised workers.
CLIN ALLERGY 9 109
136. Cleare,M.J., Hughes,E.G. et al (1976) Immediate (type I) allergic responses to platinum compounds.
CLIN ALLERGY 6 183
137. Pepys,J., Pickering,C.A.C., Hughes,E.G. (1972) Asthma due to inhaled chemical agents: complex salts of platinum. CLIN ALLERGY 2 391

138. Freedman, S.O., Krupey, J. (1968) Respiratory allergy caused by platinum salts. J ALLERGY 42 233
139. Smith, A.R. (1931) Chronic poisoning with manifestation of sensitisation. J AMER MED ASSOC 97 95
140. McConnell, L.H., Fink, J.N., Schlueter, D.P. et al (1973) Asthma caused by nickel sensitivity. ANN INTERN MED 78 888
141. Mathews, K.P., Pan, P.M. (1968) Immediate type hypersensitivity to phenyl mercuric compounds. AMER J MED 44 310
142. Pimentel, J.L. et al (1975) Respiratory disease caused by synthetic fibres. THORAX 30 204
143. Ward, M.J., Davies, D. (1983) Asthma due to grinding epoxy resin cured with phthalic anhydride. CLIN ALLERGY 13 165
144. (1977) Asthma induced by Epoxy Resin Systems. BR MED J 2 655
145. Nava, C. et al (1974) Allergic pathology Epoxy Resins SECURITAS 59 468-486
146. Allen, A., Kaidbey, K. (1979) Persistent photosensitivity following occupational exposure to Epoxy Resin. ARCH DERMATOL 115 1307-1310
147. Hosein, H.R. (1980) Some recent experiences with Epoxy Resin grouting compounds. AMER IND HYG ASSOC J 41 523
148. Meadway, J. (1980) Asthma & atopy in workers with an epoxy adhesive. BR J DIS CHEST 74 149-154
149. Calnan, C.D. (1975) Epoxy Resin Dermatitis J SOC OCCUP MED 25 123-126
150. Fregert, S., Rorsman, H. (1964) Allergens in epoxy resins ACTA ALLERGOLOGICA 19 296

151. Bourne, L.G. et al (1959) Health problems of Epoxy Resins & amine curing agents. BR J IND MED 16 189
152. Rice, D.L. et al (1977) Chemical pneumonitis secondary to inhalation of Epoxy Pipe coating.
ARCH ENVIRON HEALTH 32 173
153. Dernehl, C.U. (1963) Hazards to health associated with the use of epoxy resins. J OCCUP MED 5 17
154. Fuchs, S., Valade, P. (1951) Etude clinique et experimentale sur quelques cas d'intoxication par de desmoduir T(diisocyanate de toluylene 124 et 126).
ARCHS MAL PROFESS 12 191
155. Tanser, A.R. et al (1973) Isocyanate asthma: respiratory symptoms caused by diphenyl methyl diisocyanate
THORAX 28 596-600
156. Karol, M.H. et al (1978) TolyI specific IgE antibodies to workers with hypersensitivity to TDI.
AMER IND HYG ASSOC J 39 454-458
157. Taylor, G. (1970) Immune responses to TDI exposure in man. PROC ROY SOC MED 63 379
158. Brugsch, H.G., Elkins, H.G. (1963) Toluene di-isocyanate toxicity. NEW ENG MED J 268 353
159. Pepys, J. (1972) Asthma due to inhaled chemical agents: Toluene di-isocyanate. CLIN ALLERGY 2 225-236
160. Siracusa, A. et al (1978) Reccurent nocturnal asthma due to Tolylene diisocyanate, a case report.
CLIN ALLERGY 8 195-201
161. Bruckner, H.C. et al (1968) Clinical & immunologic appraisal of workers exposed to isocyanates.
ARCH ENVIRON HEALTH 16 619

162. Konzen, R.B. et al (1966) Human response to low concentrations of p-diphenyl methane diisocyanate (MDI).
AMER IND HYG ASS J 27 121
163. Weill, H. et al (1975) Respiratory effects in TDI manufacture. ENVIRON HEALTH PERSPECT 11 101-108
164. Duprat, P. et al (Irritant & allergenic properties of TDI & MDI. EUR J TOXICOL 9 41-53
165. Charles, J. et al (1976) Hypersensitivity Pneumonitis after exposure to isocyanates. THORAX 31 127-136
166. Tyrer, F.H. (1979) Hazards of spraying with two-pack paints containing isocyanates.
J SOC OCCUP MED 29 22-24
167. Harris, M.G. et al (1979) Isocyanate asthma - respiratory symptoms due to 1,5 naphthylene diisocyanate.
THORAX 34 762-766
168. Zeiss, C.R. et al (1980) IgE mediated asthma and hypersensitivity pneumonitis with precipitating antihapten antibodies due to diphenyl methane diisocyanate (MDI). J ALLERGY CLIN IMMUNOL 65 346-352
169. Fink, J.N., Schlueter, D.P. (1978) Bathtub finishers lung: An unusual response to TDI.
AMER REV RESP DIS 118 955
170. O'Brien, M. et al (1979) TDI induced asthma: 1. Reactions to TDI, MDI, HDI & histamine. CLIN ALLERGY 9 1
171. O'Brien, I.M. et al (1979) Toluene diisocyanate asthma: Inhalation challenge tests and bronchial reactivity studies. CLIN ALLERGY 9 7
172. Routledge, R. (1971) Contact dermatitis & bronchial irritation due to ammonium acrylate in the motor industry. TRANS SOC OCCUP MED 21 59

173. Kennes, B. et al (1981) Asthma from plexiglas powders
CLIN ALLERGY 11 49
174. Nethercott, J.R. (1981) Allergic contact dermatitis
due to epoxy acrylate.
Br J DERMATOL 104 697
175. Calnan, C.D. (1979) Cyanoacrylate dermatitis
CONTACT DERM 5 165-167
176. Keskinen, H. et al (1981) ECG ink as a cause of asthma
ALLERGY 36 275
177. Conde-Salazar, L. et al (1982) Allergic contact dermatitis
from diazo paper. CONTACT DERM 8 210
178. Ancora, A. et al (1982) Dermatitis from azo dye in
industrial leather protective shoes.
CONTACT DERM 8 220
179. Tilsley, D.A (1975) Contact and photocontact
dermatitis from Nyloprint
CONTACT DERMATITIS 1 334
180. Pepys, J., Hutchcroft, B.J. (1975) Bronchial provocation
tests in etiologic diagnosis and analysis of asthma
AMER REV RESP DIS 112 829-859
181. Pepys, J. et al (1974) The effects of inhaled
beclomethasone dipropionate (Becotide) and sodium
cromoglycate on asthmatic reactions to provocation tests
CLIN ALLERGY 4 13
182. Pepys, J. (1979) The mast cell and mode of action of
sodium cromoglycate. pp821-824
(Butterworths.)

183. Rycroft, R.J.G. (1980) Allergic contact sensitisation to epoxide 7 in grinding oil. CONTACT DERM 6 316-320
184. Malten, K.E., Zielhuis, R.L. (1964) Industrial toxicology & dermatology in the production & processing of plastics. (Elsevier Monographs.)
185. Fisher, A.A. (1973) Contact Dermatitis . 2nd Edn. pl80 (Lea & Febiger.)
186. Grandjean, E. (1957) The danger of dermatoses due to cold setting ethoxyline resins. BR J IND MED 14 1
187. Rycroft, R.J.C., Calnan, C.D. (1976) Industrial skin diseases. B J HOSPITAL MEDICINE 15 547
188. Thorgerisson, A. et al (1975) Allergenicity of epoxy resin diluents in the G.pig.
BERUFSDERMATOSEN 23 178-183
189. Thorgerisson, A. (1977) Allergenicity of epoxy resins in the G.pig. ACTA DERMATO VENEROL 57 253-256
190. Thorgerisson, A. (1978) Sensitisation capacity of epoxy resin oligomers in the g.pig.
ACTA DERMATO VENEROL 58 17-22
191. Thorgerisson, A. (1978) Sensitisation capacity of epoxy resin diluent in the G.pig.
ACTA DERMATO VENEROL 58 329-331
192. Thorgerisson, A. (1978) Sensitisation capacity of epoxy resin hardeners in the G.pig.
ACTA DERMATO VENEROL 58 322-336
193. Guidance Note EH 16 (1979) Isocyanates: toxic hazards & precautions. (Health & Safety Executive.)
194. Guidance Note MS 8 (1983) Isocyanates: medical surveillance. (Health & Safety Executive.)

195. Mowe, G. (1980) Health risks from isocyanates.
CONTACT DERM 6 44-45
196. Munn, A. (1965) Hazards of isocyanates.
ANN OCC HYGIENE 8 163
197. Dodson, V.N. (1966) Asthma & TDI exposure.
J OCCUP MED 8 81
198. Maxon, F.C. (1964) Respiratory irritation from TDI.
ARCH ENVIRON HEALTH 8 755
199. Oleru, U.G. (1980) Respiratory function study of
Nigerian workers in a TDI foam plant.
AMER IND HYG AAOC J 41 595
200. White, W.G. et al (1980) Isocyanate induced asthma
in a car factory. LANCET 1/8171 756-760
201. Butcher, B.T. et al (1979) Inhalation challenge &
pharmacologic studies of TDI sensitive workers.
J ALLERGY CLIN IMMUNOL 64 146
202. O'Brien, I.M. et al (1976) Toluene diisocyanate
pulmonary disease: Immunologic & inhalation challenge
studies. J ALLERGY CLIN IMMUNOL 58 89
203. Clarke, C.W., Aldous, P.M. (1981) Isophorone diisocyanate
induced respiratory disease.
AUST N Z J MED 11 290
204. Malo, J., Zeiss, C.R. (1982) Occupational hypersensitivity
pneumonitis after exposure to Diphenyl Methane
Diisocyanate. AMER REV RESP DIS 125 113
205. Zeiss, C.R. et al (1979) IgG & IgE antibodies in workers
with diphenyl methane diisocyanate induced respiratory
reactions. J ALLERGY CLIN IMMUNOL 63 150
206. Peters, J.M., Wegman, D.H. (1975) Epidemiology of Toluene
diisocyanate (TDI) induced respiratory disease
ENV HEALTH PERSPEC 11 97

207. Nethercott, J., Jalcubovic, H. et al (1983) Allergic contact dermatitis due to urethane acrylate in UV cured inks. B J IND MED 40 241-250
208. Pedersen, N.B. (1980) Allergy from NAPP CONTACT DERM 6 35
209. Emmett, E.A., Kominsky, J.R. (1977) Allergic contact dermatitis from UV cured inks. J OCCUP MED 19 113-115
210. Emmett, E.A. (1977) Contact dermatitis from polyfunctional acrylic monomers. CONTACT DERM 3 245-248
211. Smith, W.D.L. (1977) Allergic dermatitis due to triacrylate in UV cured inks. CONTACT DERM 3 312-314
212. Bjorkner, B. et al (1980) Allergic contact dermatitis from acrylates in UV cured inks. CONTACT DERM 6 405
213. Nethercott, J.R. (1978) Skin problems associated with multifunctional acrylic monomers in UV curing inks. B J DERMATOL 98 541
214. Emmett, E.A. et al (1977) Phototoxicity occurring during the manufacture of UV cured ink. ARCH DERMATOL 113 770-775
215. Pye, R.J., Peachey, R.D.G. (1976) Contact dermatitis due to Nyloprint. CONTACT DERM 2 144-146
216. Tilsley, D.A. (1975) Contact and photodermatitis from Nyloprint. CONTACT DERM 1 335
217. Magnusson, B., Mobacksen, H. (1972) Allergic contact dermatitis from acrylate printing plates in a printing plant. BERUFSDERMATOSEN 20 138-142
218. Fregert, S. (1974) MANUAL OF DERMATOLOGY 155

219. Jordan,W.P. (1975) Cross-sensitisation patterns in acrylate allergies. CONTACT DERM 1 13-15
220. Wahlberg,J.E. (1974) Contact sensitivity to Nylo-print printing plates.
CONTACT DERM NEWSLETTER 16 510-511
221. Maibach,H.I. et al (1978) Butyl methacrylate monomer and ethyl methacrylate monomer - frequency of reaction.
CONTACT DERM 4 60
222. Pegum,J.S. (1971) Contact dermatitis from penetration of rubber gloves by acrylic monomer.
BR MED J 5754 141
223. Calas,E. et al (1977) Allergic contact dermatitis to a photopolymerisable resin used in printing.
CONTACT DERM 3 186-194
224. Mahe-Pigotte,A. (1976) Resins used in printing: intolerance phenomena and prevention.
M.D. THESIS (Marseille Faculty of Medicine) ABSTRACT.
225. Malten,K.E. (1977) Letterflex photoprepolymer sensitisation in newspaper printers due to penta erythritol tetrakis 3 mercapto propionate and 3 mercaptopropionic acid.
CONTACT DERM 3 257
226. Malten,K.E. (1977) Contact sensitisation to Letterflex urethane photoprepolymer mixture used in printing.
CONTACT DERM 3 115
227. Jordan,W.P. (1971) Contact dermatitis from IPPD
ARCH DERM 103 85-87
228. Cavelier,C. et al (1977) Occupational eczema from IPPD & DMPPD in tyres. CONTACT DERM 3 1-15
229. Foussereau,J. (1977)
DERMATOLOGICA 155 164-168

230. Wilkinson,D.S. (1968) Sensitivity to IPPD
CONTACT DERM NEWSLETTER 2 5
231. Calnan,C.D. (1971) Lichenoid dermatitis from IPPD
CONTACT DERM NEWSLETTER 4 237
232. Ancona,A. et al (1982) Occupational dermatitis from
IPPD in tyres. CONTACT DERM 8 91
233. Kilplkari,I. (1982) Occupational contact dermatitis
amongst rubber workers. CONTACT DERM 8 359
234. Fregert,S. (1968) Contact dermatitis from colophony
used as a print proteoline coating.
CONTACT DERM NEWSLETTER 4 58
235. Calnan,C. (1972) Colophony dermatitis from insulated
tools. CONTACT DERM NEWSLETTER 1 9
236. Wilkinson,D.S., Calnan,C.D. (1975) Rosin used for
betdine machine. CONT DERM 1 64
237. Davidson,J.M. (1941) Toxic effects of iroko: an
African wood. LANCET 1 30
238. Cronin,E. (1980) Contact Dermatitis pp548-573
(Churchill Livingstone.)
239. Calnan,C.D. (1969) Dithianone sensitivity
CONTACT DERM NEWSLETTER 6 119
240. Schmidt,H. (1978) Contact uticaria to teak with
systemic effects. CONT DERM 4 176
241. Cronin,E., Calnan,C.D. (1975) Rosewood knife handle
CONT DERM 1 120
242. Hausen,B.M. (1982) Incidence & importance of primary
irritant & allergic contact dermatitis due to Machaerevin
scleroxylum tul (Pao ferro) a substitute for Brazilian
Rosewood Dalbergia nigra all.
HAUTARZT 33 321 ABSTRACT

243. Bleumink, E. et al (1973) Allergic contact dermatitis
from cedarwood (Thuja plicata)
B J DERMATOL 88 499
244. The Merck Index (1983) 10th Edn. (Merck & Company).
245. Guidance Note EH 40 (1984)
(Health & Safety Executive.)
246. O'Quinn, S.E., Kennedy, C.B. (1965)
J AMER MED ASSOC 194 123
247. Kane, L.E., Alarie, Y. (1977)
AMER IND HYG ASSOC J 38 509
248. Schoenberg, J.B., Mitchell, C.A. (1975) Airway disease
caused by phenolic (Phenol-formaldehyde) resin exposure
ARCH ENVIRON HEALTH 30 574
249. Hendrick, D.J., Lane, D.J. (1977) Occupational formalin
asthma. B J IND MED 34 11-18
250. Hendrick, D.J., Lane, D.J. (1975) Formalin asthma in
hospital staff. B. MED J 1 607
251. Sakula, A. (1975) Formalin asthma in hospital lab.
staff. LANCET 2 816
252. Popa, V. et al (1969) Bronchial asthma & asthmatic
bronchitis determined by simple chemicals
DISEASES OF THE CHEST 56 395
253. Vaughan, W.T. (1954) The Practice of Allergy, 3rd Edn
p677 (Kingston.)
254. Hendrick, D.J. et al (1982) Formaldehyde asthma:
challenge experimental levels & fate after 5 years
J OCCUP MED 24 893
255. Harris, J.C. et al (1981) Toxicology of urea formaldehyde
& polyurethane foam insulation.
J AMER MED ASSOC 245 243

256. Bardana, J. (1980) Formaldehyde: Hypersensitivity & irritant reactions at work and in the home.
IMMUNOL ALLERGY PRACT 11 11-23
257. Porter, A.H. (1975) Acute respiratory distress following formalin inhalation. LANCET 2 603
258. Pedersen, N.B. (1980) Occupational hand eczema from formaldehyde in price labels. CONTACT DERM 6 57
259. Simpson, J. (1969) Formalin sensitivity - offset printing machine. CONTACT DERM NEWSLETTER 6 133
260. Black, H. (1971) Contact dermatitis from formaldehyde in newsprint. CONTACT DERM NEWSLETTER 10 242
261. Fabry, H. (1968) Formaldehyde sensitivity
CONTACT DERM NEWSLETTER 3 51
262. Sneddon, I.B. (1968) Formalin dermatitis in a renal dialysis unit. CONTACT DERM NEWSLETTER 3 47
263. Abdel-Aziz, A.H.M., Hodgson, C. (1974) Formalin dermatitis in a renal dialysis unit.
CONTACT DERMATITIS NEWSLETTER 15 441
264. Bandman, H.J., Breit, R., Mutzeck, E. (1974) Allergic contact dermatitis from formaldehyde in a brewer.
CONTACT DERM NEWSLETTER 15 452
265. Wilkinson, D.S. (1970) Formalin sensitivity in mushroom farming. CONTACT DERM NEWSLETTER 7 162
266. Fregert, S. (1968) Allergic contact dermatitis from formaldehyde formed at oil tannage.
CONTACT DERM NEWSLETTER 3 45
267. Houding, G. (1969) Occupational dermatitis from pyrolysis product of polythene. ACTA DERMATO VENEROL 49 147

268. Cooke, M.A., Wilkinson, J.F. (1973) Formalin sensitivity
in gum arabic. CONTACT DERM NEWSLETTER 13 379
269. Lindskov, R. (1982) Contact urticaria to formaldehyde
CONTACT DERM 8 333
270. (1959)
ACTA DERMATO VENEROL 39 450
271. Fisher, A. (1976) Formaldehyde: some recent experiences
CUTIS 17 665
272. Fregert, S. (1974) Allergic contact dermatitis from
formaldehyde in paper. CONTACT DERM NEWSLETTER 15 459
273. O'Quinn, S.E., Kennedy, B. (1965)
J AMER MED ASSOC 194 593
274. Schoor, W.F. (1971) Formaldehyde in shampoos & toiletries
CONTACT DERM NEWSLETTER 9 220
275. Glass, W. (1961)
N.Z. MED J 60 423
276. Markusson, K.E., Mancuso, T.F. (1943)
IND MED 12 383
277. Logan, W.S., Perry, H.O. (1972) Formaldehyde sensitivity
dermatitis. ARCH DERMATOL 106 717
278. Cronin, E. (1980) Contact Dermatitis, pp 791-793
(Churchill Livingstone.)
279. Hendrick, D.J. (1983) The formaldehyde problem : A
clinical approach.
IMMUNOL ALLERGY PRACT 5 97-108
280. Fisher, A.A. (1981) Reactions to glutaraldehyde with
particular reference to radiologists & X-ray technicians.
CUTIS 28 113

281. Sanderson,K.V., Cronin,E. (1968) Glutaraldehyde and Contact dermatitis. BR MED J 3 802
282. Jordan,W.P. et al (1972) Contact dermatitis from glutaraldehyde. ARCH DERMATOL 105 94
283. Skog,E. (1968) Sensitivity to glutaraldehyde CONTACT DERM NEWSLETTER 4 79
284. Harman,R.R.M., O'Grady,K.J. (1972) Contact dermatitis due to sensitivity to Cidex (activated Glutaraldehyde) CONTACT DERM NEWSLETTER 11 279
285. Neering,H., Ketel, Van. (1974) Glutaraldehyde & formaldehyde allergy. CONTACT DERM NEWSLETTER 16 518
286. Lyen,T.C. (1971) Allergic contact dermatitis due to Cidex. ORAL SURGERY 32 895
287. Clayton,G.D., Clayton,F.E. (Eds.) (1981) Patty's Industrial Hygiene & Toxicology, 3rd Edn. (John Wiley & Sons.)
288. Cockcroft,D.W. et al (1980) Asthma caused by occupational exposure to a furan based binder system. J ALLERGY CLIN IMMUNOL 66 458
289. Nethercott,J.R. et al (1983) Contact dermatitis due to cinnamic aldehyde in deodorant manufacturing process CONT DERM 9 241-242
290. Bonnevie,P. (1948) Some experiences of wartime induced dermatoses. ACTA DERM VENEROL 28 231-237
291. Collins,F.W., Mitchell,J.C. (1975) Aroma chemicals CONT DERM 1 43-47
292. Hausen,B.M., Schmalle,H. (1981) Quinonoid constituents as contact sensitisers in Australian blackwood (Acacia melanoxylan RBR) BR J IND MED 38 105

293. Hausen, B.M., Schulz, K.H. (1977) On the sensitising of naturally occurring quinones III : A new contact allergen (2-dimethyl allyl 1,4 benzoquinone) from phagnalon sp. PLANTA MED 32 287-296
294. Miller, M. et al (1978) Allergic contact dermatitis to quinone derivative (felt tip pen ink) ARCH DERMATOL 114 1793-1794
295. Gardiner, J.S. et al (1972) The investigation of photo-contact dermatitis in a dye manufacturing process. B J DERMATOL 86 264-271
296. Schulz, K.H. (1962) BERUFSDERMATOSEN 10 17
297. Raymond, J.Z., Gross, P.R. (1969) EDTA : Preservative dermatitis. ARCH DERMATOL 100 436
298. Henck, J.W. (1980) Skin sensitisation potential of trisodium EDTA. DRUG CHEM TOXICOL 3 99-103
299. Wilkinson, D.S. (1972) Sensitivity to pharmaceutical additives. in 'Drug Allergy' Dash, C.H., Jones, H.E.H. (Eds.) Glaxo symposium
300. Chang Yeung, M. et al (1980) Activation of complement by plicatic acid. J ALLERGY CLIN IMMUNOL 65 333
301. Bariana, D.S. et al (1965) NATURE 207 1155
302. Burge, P.S. et al (1979) Occupational asthma due to inhaled carmine. CLIN ALLERGY 9 185
303. Sarkany, I., Meara, R.H., Everall, J. (1961) TRANS ST JOHN HOSP DERM SOC 46 39
304. Kammermeyer, J.K., Mathews, K.P. (1973) Hypersensitivity to phenyl glycine acid chloride, J ALLERGY CLIN IMMUNOL 52 73-84

305. Kern,R.A. (1939) Asthma & rhinitis due to sensitisation to phthalic anhydride, report of a case.
J ALLERGY 10 164-167
306. Gervais,P. et al (1972) Diagnosis and psychopathology of asthma due to phthalic anhydride, value of lymphoblastic transformation test.
EUR J TOXICOL 5 106-109
307. Maccia,A.C. et al (1976) In vitro demonstration of specific IgE in phthalic anhydride hypersensitivity
AMER REV RESP DIS 113 701
308. Chester,E.H. et al (1977) Phthalic anhydride asthma
CLIN ALLERGY 7 15-20
309. Pauli,G. et al (1980) Meat wrapper's asthma : identification of the causal agent
CLIN ALLERGY 10 263
310. Schueter,D.P. et al (1978) Occupational asthma due to tetrachlorophthalic anhydride
J OCCUP MED 20 183-188
311. Zeiss,E.R. et al (1977) Trimellitic anhydride induced airway syndromes : chemical & immunologic studies
J ALLERGY CLIN IMMUNOL 60 96-103
312. Sale,S.R. et al (1980) Chemical & immunologic correlations in TMA airway syndromes
J ALLERGY CLIN IMMUNOL 68 188
313. Patterson,R. et al (1979) Antihapten antibodies in workers exposed to Trimellitic Anhydride Pulmonary Disease-Anaemia Syndrome
AMER REV RESP DIS 120 1259-1267
314. Pedersen,N.B. (1976) Occupational allergy from 1,2-benzisothiazolin-3-one and other preservatives in plastic emulsions . CONT DERM 2 340-342

315. Slovak, A.J.M. (1981) Occupational asthma caused by a plastics blowing agent azodicarbonamide
THORAX 36 906
316. Fregert, S. (1978) Allergic contact dermatitis from ethyl acrylate in a window sealant
CONTACT DERM 4 56
317. Bjorkner, B. (1980) Allergenicity of trimethylol propane triacrylate in UV curing inks in the G.pig
ACTA DERM VENEREOL 68 528
318. Goldman, P. (1963)
HAUT & GESCHLECHTSKRANKHEITEN 25 14 (SUMMARY)
319. Malten, K.E., Zielhuis, R.L. (1964) Industrial Toxicology and Dermatology in the Production and Processing of Plastics. (Elsevier Monographs.)
320. Magnusson, B., Mobacken, H. (1972) Contact allergy to self-hardening acrylic sealer for assembling metal parts
BERUFSDERMATOSEN 20 198
321. Chung, C.W. et al (1977) Sensitization potentials of ethyl, methyl & n-butyl methacrylates and mutual cross sensitivity in G pigs
J INVEST DERM 68 187-190
322. Malten, K.E. (1979) Rubber chemicals & acryl resins acting as contact sensitisers.
ALLERGOLOGIE 2 285-295
323. Malten, K.E., Bende, W.J.M. (1979) 2-Hydroxy-ethyl-methacrylate and di- and tetra ethylene glycol di-methacrylate : Contact sensitisers in a photoprepolymer printing plate procedure. CONTACT DERM 5 214-220

324. Whittington, C.V. (1981) Dermatitis from UV acrylate in adhesive. CONTACT DERM 7 203-204
325. Malten, K.E. et al (1978) Nyloprint-sensitive patients react to N,N' methylene bis acrylamide.
CONTACT DERM 4 214-222
326. Fregert, S., Dahlquist, I. (1969) Allergic contact dermatitis from N methylol acrylamide
CONTACT DERM NEWSLETTER 5 102
327. Balda, B.R. (1971) Allergic contact dermatitis due to acrylonitrile. CONTACT DERM NEWSLETTER 9 219
328. Pedersen, N.B. et al (1982) Secondary acrylamides in Nyloprint printing plates as a source of contact dermatitis. CONTACT DERM 8 223
329. Cronin, E (1968) Studies in contact dermatitis XVIII
Dyes in clothing
TRANS ST JOHNS HOSP DERMATOL 54 156-164
330. Simon, F.A., Rackeman, F.M. (1934) Contact eczema due to clothing. J AMER MED ASSOC 102 127
331. Kgzuka, T. et al (1980) Pigmented contact dermatitis from azo dyes. CONTACT DERM 6 330
332. Kgzuka, T. et al (1979) Brilliant Lake Red R as a cause of pigmented contact dermatitis. CONTACT DERM 5 297
333. Alanko, K. et al (1978) Immediate type hypersensitivity to reactive dyes. CLIN ALLERGY 8 25
334. Evans, W.V., Seaton, A. (1979) Hypersensitivity pneumonitis in a technician using Pauli's reagent.
THORAX 34 767-770
335. Rodenstein, D., Stanescu, D.C. (1982) Bronchial asthma following exposure to ECG ink. ANN ALLERGY 48 351

336. Rycroft, R.J.G. (1980) Allergic contact sensitisation to epoxide 7 in grinding oil. CONTACT DERM 6 316-320
337. Carpenter, C.P. et al (1948) Ethylene imine skin sensitivity. J IND HYG TOXIC 30 2
338. Lam, S., Chan Yeung, M. (1980) Ethylene Diamine induced asthma. AMER REV RESP DIS 121 151-155
339. Gelfand, H.H. (1963) Respiratory allergy due to chemical compounds encountered in the rubber, shellac and beauty culture industries. J ALLERGY 34 374
340. (1956)
J PHARMACOL EXP THERAPY 116 139
341. Rudzki, E. (1976) Cross-reactions between ethylene diamine, diethylene tetramine and triethyl tetramine CONTACT DERM 2 311-313
342. Crow, K.D. et al (1978) Coolant oil dermatitis due to ethylene diamine. CONTACT DERM 4 359-361
343. Wuthrich, B. (1972) Occupational eczema caused by ethylene diamine in the manufacture of synthetic fibres BERUFSDERMATOSEN 20 200-203
344. Marzulli, F.N., Maibach, H.I. (1976) Contact allergy: predictive testing in man. CONTACT DERM 2 1-17
345. Provost, T.T., Jillson, O.F. (1967) Ethylene diamine contact dermatitis. ARCH DERMATOL 96 231
346. White, I.M. et al (1978) Contact dermatitis attributed to ethylene diamine. B MED J 1 415
347. Marzulli, T.N., Maibach, H.I. (1973) Antimicrobials: experimental contact sensitisation in man.
J SOC COS CHEM

348. Evans,D.M. (1959)
B J IND MED 16 126
349. (1951)
IND MED SURGERY 20 541
350. Ryan,G. et al (1980) Occupational asthma due to
diethylene triamine. AMER REV RESP DIS 121 253
351. Dernehl,C.V. (1951) Clinical experiences with exposures
to ethylene amines. IND MED SURG 20 54
352. Pepys,J. et al (1972) Asthma due to inhaled chemical
agents - piperazine dihydrochloride.
CLIN ALLERGY 2 189
354. Hagmar,L. et al (1982) Piperazine- induced occupational
asthma. J OCCUP MED 24 193
355. Rudzki,E., Grzywa,Z. (1977) Occupational piperazine
dermatitis. CONT DERM 3 216
356. Calnan,C.D. (1975) Occupational piperazine dermatitis
CONTACT DERM 1 126
357. Cornish,H.H., Block,W.D. (1959) The toxicology of uncured
epoxy resins and amine curing agents
AMER ARCHIVES IND HEALTH 20 390
358. (1959)
B J IND MED 16 81
359. Osmundsen,P,E. (1970) Pigmented contact dermatitis
B J DERMATOL 83Z 296-301
360. Vallieres,M. et al (1977) Dimethyl ethanolamine
induced asthma. AMER REV RESP DIS 115 867
361. Sterling,G.M. (1967) Asthma due to aluminium soldering
flux. THORAX 22 533

362. Pepys, J., Pickering, C.A. (1972) Asthma due to inhaled chemical fumes: amino ethyl ethanolamine in aluminium soldering flux. CLIN ALLERGY 2 197
363. Dijkman, J.H. et al (1981) Occupational asthma due to inhalation of chloramine T . I. Clinical observations and inhalation provocation studies
INT ARCH ALLERGY APPL IMMUNOL 64 422
364. Framps, J.A. et al (1981) Occupational asthma due to inhalation of chloramine T . II. Demonstration of specific IgE antibody.
INT ARCH ALLERGY APPL IMMUNOL 64 428
365. Bourne, M.D. et al (1979)
B MED J 3 10
366. Stern, F. (1949)
ACTA PHARMACOL TOXICOL 5 1
367. (1959)
J ALLERGY 30 11
368. Landsteiner, K., Jacobs, J. (1935) Studies on the sensitisation of animals with simple chemical compounds
J EXP MED 61 643
369. Sampter, M., Parker, C.W. (Eds.) (1972) Hypersensitivity to drugs. (Pergamon Press.)
370. Ozaki, S. (1972) Recent advances in isocyanate chemistry
CHEM REVIEWS 72 457
371. Marcarli, K. (1957) Microdetermination of TDI in atmosphere. ANALYTIC CHEMISTRY 29 552
372. Tse, K.S. et al (1982) Specific IgE antibody in workers with occupational asthma to Western Red Cedar
CLIN ALLERGY 12 249

373. Paggiaro, P.L. et al (1983) Absence of IgG antibody to TDI-HSA in a RAST study. CLIN ALLERGY 13 75-79
374. Dewair, M.A., Baur, X. (1982) Studies on antigens useful for detection of IgE antibody in isocyanate sensitised workers.
J CLIN CHEM CLIN BIOCHEM 20 337-340
375. Butcher, B.T. et al (1977) Toluene diisocyanate pulmonary disease lymphoblastic and mechoyl challenge studies
J ALLERGY CLIN IMMUNOL 59 223
376. Karol, M.H. et al (1978) Hapten specific respiratory sensitivity in Guinea pigs.
AMER IND HYG ASSOC J 39 546
377. Karol, M.H. et al (1979) Pulmonary hypersensitivity to hexyl isocyanate-ovalbumin aerosol in guinea pigs.
TOXICOL APP PHARMACOL 51 73
378. Tse, C.S.T. et al (1979) Induction of murine reaginic antibodies by Toluene diisocyanate
AMER REV RESP DIS 120 829
379. Tse, C.S.T., Pesce, A.J. (1979) Chemical characterisation of isocyanate protein conjugates.
TOXICOL APP PHARMACOL 51 39
380. Karol, M.H., Alarie, Y. (1980) Antigens which detect IgE antibody in workers sensitive to TDI
CLIN ALLERGY 10 101-109
381. Butcher, B.T. et al (1980) RAST test of TDI reactive individuals using p-tolyl isocyanate antigen
J ALLERGY CLIN IMMUNOL 66 213

382. Karol, M.H. et al (1981.) Dermal contact with TDI produces respiratory tract hypersensitivity in G.pigs
TOXICOL APP PHARMACOL 58 221
383. Danks, J.M. et al (1981) TDI induced asthma evaluation of antibody in the serum of affected workers against a tolyl mono isocyanate protein conjugate
CLIN ALLERGY 11 161
384. Butcher, B.T. et al (1982) Development and loss of TDI reactivity: immunologic, pharmacologic and provocation challenge studies. J ALLERGY CLIN IMMUNOL 70 231
385. Chen, S.E., Bernstein, I. (1982) G.pig model of diisocyanate sensitisation I. Immunologic studies
J ALLERGY CLIN IMMUNOL 70 383.
386. Bernstein, I. et al (1982) G.pig model of diisocyanate sensitisation II. Physiologic studies
J ALLERGY CLIN IMMUNOL 70 393
387. Van de Walle, H.B. et al (1982) Sensitising potential of 14 mono (meth)acrylates in the G. pig
CONTACT DERM 8 223
388. Majeti, V.A., Suskind, R.R. (1977) Mechanism of cinnamaldehyde sensitivity. CONTACT DERM 3 16
389. Patterson, R. et al (1978) Human antihapten antibodies in TMA inhalation reactions.
J CLIN INVEST 62 971-978
390. Lachapelle, J.M., Lachapelle Ketelaur, M.J. (1979) Cross-sensitivity between isophore diamine and isophore diisocyanate. CONTACT DERM 5 55
391. Norpoth, K. (1983) Phthalic anhydride & some derivatives in Encyclopaedia of Occupational Health and Safety (3rd Edn.) pp1693-1694 (International Labour Organisation)

392. Cronin,E. (1980) Contact Dermatitis pp 595-614
(Churchill Livingstone.)
393. Pauli,G. et al (1980) Meat wrapper's asthma
CLIN ALLERGY 10 263-269
394. Shelley,W.B., Juhlin,L. (1977) Selective uptake of
contact allergens by the Langerhans cell
ARCH DERMATOL 113 187
395. Silberberg,I., Baer,R.L., Rosenthal,S.A. (1976)
The role of Langerhans cells in allergic contact
hypersensitivity: A review of findings in man and the
guinea pig. J INVEST DERMATOL 66 210
396. Stingl,G., Katz,S.I. et al (1978) Immunologic functions
of Ia bearing epidermal Langerhans cells
J IMMUNOL 12 2005
397. Brostoff,J., Roitt,I.M. (1969) Cell mediated (delayed)
hypersensitivity in patients with summer hay fever
LANCET 2 1269
398. Thomas,W.R., Asherson,G.L., Watkins,M.L. (1976)
Reaginic antibody produced in mice with contact
sensitivity. J EXP MED 144 1386
399. Platts Mills,T.A.E. (1981) The biological role of
allergy in 'Immunological & Clinical aspects of Allergy'
Lessoof,M.H. (Ed.) pp 30-31 (MTP Press Ltd.)
400. Platts Mills,T.A.E. (1981) The biological role of
allergy in 'Immunological & Clinical aspects of Allergy'
Lessoof,M.H. (Ed.) pp15-17
401. Alberman,K. (1981) Barrier Creams - more than a tradition
HEALTH & SAFETY AT WORK Aug 1981 pp32-33

402. Guidance Note EH 27 (1981) Acrylonitrile: personal protective equipment. (Health & Safety Executive.)
403. Guidance Note MS 4 (1977) Organic Dust Surveys (Health & Safety Executive.)
404. Prentice, J. (1960) Environmental Monitoring
HEALTH & SAFETY AT WORK March 80 pp28-31
405. Guidance Note MS 20 (1982) Pre Employment health screening. (Health & Safety Executive.)
406. Guidance Note MS 18 (1981) Health surveillance by routine procedures (Health & Safety Executive.)
407. Juniper, C.P. (1975) Respiratory Allergies in Industry:
A review of recent advances and current clinical practice. J SOC OCCUP MED 25 50-57
408. Guidance Note MS 3 (1977) Skin testing in dermatitis and occupational chest disease. (Health & Safety Executive.)
409. Harries, M.G., Burge, P.S., O'Brien, I.M. (1980)
Occupational type bronchial provocation tests: testing with soluble antigen by inhalation.
B J IND MED 37 248-252
410. Guidance Note MS 5 (1977) Lung Function (Health & Safety Executive.)